false2024Q2000073176612/3150xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesutr:Ratexbrli:pureunh:reportableSegments00007317662024-01-012024-06-3000007317662024-07-3100007317662024-06-3000007317662023-12-3100007317662024-04-012024-06-3000007317662023-04-012023-06-3000007317662023-01-012023-06-300000731766us-gaap:ProductMember2024-04-012024-06-300000731766us-gaap:ProductMember2023-04-012023-06-300000731766us-gaap:ProductMember2024-01-012024-06-300000731766us-gaap:ProductMember2023-01-012023-06-300000731766us-gaap:ServiceMember2024-04-012024-06-300000731766us-gaap:ServiceMember2023-04-012023-06-300000731766us-gaap:ServiceMember2024-01-012024-06-300000731766us-gaap:ServiceMember2023-01-012023-06-300000731766us-gaap:CommonStockMember2024-03-310000731766us-gaap:AdditionalPaidInCapitalMember2024-03-310000731766us-gaap:RetainedEarningsMember2024-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000731766us-gaap:NoncontrollingInterestMember2024-03-3100007317662024-03-310000731766us-gaap:RetainedEarningsMember2024-04-012024-06-300000731766us-gaap:NoncontrollingInterestMember2024-04-012024-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-04-012024-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-06-300000731766us-gaap:CommonStockMember2024-04-012024-06-300000731766us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000731766us-gaap:CommonStockMember2024-06-300000731766us-gaap:AdditionalPaidInCapitalMember2024-06-300000731766us-gaap:RetainedEarningsMember2024-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000731766us-gaap:NoncontrollingInterestMember2024-06-300000731766us-gaap:CommonStockMember2023-03-310000731766us-gaap:AdditionalPaidInCapitalMember2023-03-310000731766us-gaap:RetainedEarningsMember2023-03-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000731766us-gaap:NoncontrollingInterestMember2023-03-3100007317662023-03-310000731766us-gaap:RetainedEarningsMember2023-04-012023-06-300000731766us-gaap:NoncontrollingInterestMember2023-04-012023-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-04-012023-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300000731766us-gaap:CommonStockMember2023-04-012023-06-300000731766us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000731766us-gaap:CommonStockMember2023-06-300000731766us-gaap:AdditionalPaidInCapitalMember2023-06-300000731766us-gaap:RetainedEarningsMember2023-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000731766us-gaap:NoncontrollingInterestMember2023-06-3000007317662023-06-300000731766us-gaap:CommonStockMember2023-12-310000731766us-gaap:AdditionalPaidInCapitalMember2023-12-310000731766us-gaap:RetainedEarningsMember2023-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000731766us-gaap:NoncontrollingInterestMember2023-12-310000731766us-gaap:RetainedEarningsMember2024-01-012024-06-300000731766us-gaap:NoncontrollingInterestMember2024-01-012024-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-06-300000731766us-gaap:CommonStockMember2024-01-012024-06-300000731766us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300000731766us-gaap:CommonStockMember2022-12-310000731766us-gaap:AdditionalPaidInCapitalMember2022-12-310000731766us-gaap:RetainedEarningsMember2022-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000731766us-gaap:NoncontrollingInterestMember2022-12-3100007317662022-12-310000731766us-gaap:RetainedEarningsMember2023-01-012023-06-300000731766us-gaap:NoncontrollingInterestMember2023-01-012023-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-06-300000731766us-gaap:CommonStockMember2023-01-012023-06-300000731766us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300000731766unh:ProductsAndServicesMember2024-06-300000731766unh:ProductsAndServicesMember2023-12-3100007317662024-07-012024-06-300000731766us-gaap:USTreasuryAndGovernmentMember2024-06-300000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2024-06-300000731766us-gaap:CorporateDebtSecuritiesMember2024-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2024-06-300000731766us-gaap:USTreasuryAndGovernmentMember2023-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310000731766us-gaap:CorporateDebtSecuritiesMember2023-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2023-12-310000731766us-gaap:DebtSecuritiesMember2024-06-300000731766us-gaap:DebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel1Member2024-06-300000731766us-gaap:FairValueInputsLevel2Member2024-06-300000731766us-gaap:FairValueInputsLevel3Member2024-06-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2024-06-300000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2024-06-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMember2024-06-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-06-300000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel2Member2024-06-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-06-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2024-06-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-06-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2024-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2024-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Member2024-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2024-06-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2024-06-300000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel2Member2024-06-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2024-06-300000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-06-300000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-06-300000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2024-06-300000731766us-gaap:FairValueInputsLevel1Member2023-12-310000731766us-gaap:FairValueInputsLevel2Member2023-12-310000731766us-gaap:FairValueInputsLevel3Member2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2023-12-310000731766us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMember2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMemberus-gaap:FairValueInputsLevel2Member2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2023-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Member2023-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2023-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMemberus-gaap:FairValueInputsLevel2Member2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2023-12-310000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2023-12-310000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310000731766us-gaap:DebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-06-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-06-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-06-300000731766us-gaap:FairValueMeasurementsNonrecurringMember2024-06-300000731766us-gaap:LongTermDebtMember2024-06-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310000731766us-gaap:FairValueMeasurementsNonrecurringMember2023-12-310000731766us-gaap:LongTermDebtMember2023-12-310000731766unh:A4.600NotesDueApril2027Member2024-03-310000731766unh:A4.700NotesDueApril2029Member2024-03-310000731766unh:A4.900NotesDueApril2031Member2024-03-310000731766unh:A5.000NotesDueApril2034Member2024-03-310000731766unh:A5.375NotesDueApril2054Member2024-03-310000731766unh:A5.500NotesDueApril2064Member2024-03-310000731766us-gaap:SubsequentEventMember2024-07-310000731766unh:FloatingRateNotesDueJuly2026Memberus-gaap:SubsequentEventMember2024-07-310000731766unh:A4.750NotesDueJuly2026Memberus-gaap:SubsequentEventMember2024-07-310000731766unh:A4.800NotesDueJanuary2030Memberus-gaap:SubsequentEventMember2024-07-310000731766unh:A4.950NotesDueJanuary2032Memberus-gaap:SubsequentEventMember2024-07-310000731766unh:A5.150NotesDueJuly2034Memberus-gaap:SubsequentEventMember2024-07-310000731766unh:A5.500NotesDueJuly2044Memberus-gaap:SubsequentEventMember2024-07-310000731766unh:A5.625NotesDueJuly2054Memberus-gaap:SubsequentEventMember2024-07-310000731766unh:A5.750NotesDueJuly2064Memberus-gaap:SubsequentEventMember2024-07-310000731766us-gaap:CommercialPaperMember2024-06-300000731766unh:May2024364DayRevolvingBankCreditFacilityMember2024-05-310000731766unh:May2024364DayRevolvingBankCreditFacilityMember2024-01-012024-06-300000731766unh:May2024364DayDelayedDrawTermLoanMember2024-05-310000731766unh:May2024364DayDelayedDrawTermLoanMember2024-01-012024-06-3000007317662024-03-192024-03-1900007317662024-06-252024-06-250000731766us-gaap:SubsequentEventMember2024-07-012024-07-310000731766us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2024-01-012024-06-300000731766us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-01-012024-06-3000007317662024-02-062024-02-060000731766us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2024-02-060000731766us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:ExternalCustomersMemberunh:OptumHealthMember2024-04-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:IntersegmentEliminationMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766unh:TotalOptumMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766unh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:ExternalCustomersMemberunh:OptumHealthMember2024-04-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumRxMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:IntersegmentEliminationMemberus-gaap:ProductMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:ProductMemberunh:TotalOptumMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:ProductMemberus-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:ProductMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:ExternalCustomersMemberunh:OptumHealthMember2024-04-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumRxMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:ServiceMemberunh:TotalOptumMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:ServiceMemberunh:ExternalCustomersMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:UnitedhealthcareMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptumHealthMember2024-04-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberunh:IntersegmentMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptumRxMember2024-04-012024-06-300000731766us-gaap:IntersegmentEliminationMemberunh:IntersegmentMember2024-04-012024-06-300000731766unh:IntersegmentMemberunh:TotalOptumMember2024-04-012024-06-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2024-04-012024-06-300000731766unh:IntersegmentMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumHealthMember2024-04-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMember2024-04-012024-06-300000731766us-gaap:IntersegmentEliminationMember2024-04-012024-06-300000731766unh:TotalOptumMember2024-04-012024-06-300000731766us-gaap:CorporateNonSegmentMember2024-04-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:ExternalCustomersMemberunh:OptumHealthMember2023-04-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:IntersegmentEliminationMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766unh:TotalOptumMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766unh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:ExternalCustomersMemberunh:OptumHealthMember2023-04-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumRxMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:IntersegmentEliminationMemberus-gaap:ProductMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:ProductMemberunh:TotalOptumMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:ProductMemberus-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:ProductMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:ExternalCustomersMemberunh:OptumHealthMember2023-04-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumRxMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:ServiceMemberunh:TotalOptumMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:ServiceMemberunh:ExternalCustomersMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:UnitedhealthcareMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptumHealthMember2023-04-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberunh:IntersegmentMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptumRxMember2023-04-012023-06-300000731766us-gaap:IntersegmentEliminationMemberunh:IntersegmentMember2023-04-012023-06-300000731766unh:IntersegmentMemberunh:TotalOptumMember2023-04-012023-06-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2023-04-012023-06-300000731766unh:IntersegmentMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumHealthMember2023-04-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMember2023-04-012023-06-300000731766us-gaap:IntersegmentEliminationMember2023-04-012023-06-300000731766unh:TotalOptumMember2023-04-012023-06-300000731766us-gaap:CorporateNonSegmentMember2023-04-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:ExternalCustomersMemberunh:OptumHealthMember2024-01-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:IntersegmentEliminationMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766unh:TotalOptumMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766unh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:ExternalCustomersMemberunh:OptumHealthMember2024-01-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumRxMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:IntersegmentEliminationMemberus-gaap:ProductMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:ProductMemberunh:TotalOptumMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:ProductMemberus-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:ProductMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:ExternalCustomersMemberunh:OptumHealthMember2024-01-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumRxMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:ServiceMemberunh:TotalOptumMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:ServiceMemberunh:ExternalCustomersMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:UnitedhealthcareMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptumHealthMember2024-01-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberunh:IntersegmentMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptumRxMember2024-01-012024-06-300000731766us-gaap:IntersegmentEliminationMemberunh:IntersegmentMember2024-01-012024-06-300000731766unh:IntersegmentMemberunh:TotalOptumMember2024-01-012024-06-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2024-01-012024-06-300000731766unh:IntersegmentMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumHealthMember2024-01-012024-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMember2024-01-012024-06-300000731766us-gaap:IntersegmentEliminationMember2024-01-012024-06-300000731766unh:TotalOptumMember2024-01-012024-06-300000731766us-gaap:CorporateNonSegmentMember2024-01-012024-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:ExternalCustomersMemberunh:OptumHealthMember2023-01-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:IntersegmentEliminationMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766unh:TotalOptumMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766unh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:ExternalCustomersMemberunh:OptumHealthMember2023-01-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumRxMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:IntersegmentEliminationMemberus-gaap:ProductMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:ProductMemberunh:TotalOptumMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:ProductMemberus-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:ProductMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:ExternalCustomersMemberunh:OptumHealthMember2023-01-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumRxMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:IntersegmentEliminationMemberus-gaap:ServiceMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:ServiceMemberunh:TotalOptumMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:ServiceMemberus-gaap:CorporateNonSegmentMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:ServiceMemberunh:ExternalCustomersMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:UnitedhealthcareMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptumHealthMember2023-01-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMemberunh:IntersegmentMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:IntersegmentMemberunh:OptumRxMember2023-01-012023-06-300000731766us-gaap:IntersegmentEliminationMemberunh:IntersegmentMember2023-01-012023-06-300000731766unh:IntersegmentMemberunh:TotalOptumMember2023-01-012023-06-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2023-01-012023-06-300000731766unh:IntersegmentMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumHealthMember2023-01-012023-06-300000731766unh:OptumInsightMemberus-gaap:OperatingSegmentsMember2023-01-012023-06-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMember2023-01-012023-06-300000731766us-gaap:IntersegmentEliminationMember2023-01-012023-06-300000731766unh:TotalOptumMember2023-01-012023-06-300000731766us-gaap:CorporateNonSegmentMember2023-01-012023-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________ 
FORM 10-Q
__________________________________________________________ 
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
Commission File Number: 1-10864
__________________________________________________________ 
UHG(R)_CMYK.jpg
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
 __________________________________________________________ 
Delaware41-1321939
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
9900 Bren Road East55343655 New York Avenue NW20001
Minnetonka,
Minnesota
Washington,DC
(Address of principal executive offices) (Zip Code)(Address of principal executive offices)(Zip Code)
(800) 328-5979
(Registrant’s telephone number, including area code)
_________________________________________________________  
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.01 par valueUNHNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer☒Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐ No ☒
As of July 31, 2024, there were 923,418,150 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.


UNITEDHEALTH GROUP
Table of Contents
 
  Page



PART I
ITEM 1.    FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)June 30,
2024		December 31,
2023
Assets
Current assets:
Cash and cash equivalents$26,286 $25,427 
Short-term investments5,037 4,201 
Accounts receivable, net23,115 21,276 
Other current receivables, net26,762 17,694 
Assets under management3,414 3,755 
Prepaid expenses and other current assets7,424 6,084 
Total current assets92,038 78,437 
Long-term investments46,113 47,609 
Property, equipment and capitalized software, net
9,801 11,450 
Goodwill105,436 103,732 
Other intangible assets, net14,729 15,194 
Other assets17,939 17,298 
Total assets$286,056 $273,720 
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable$32,547 $32,395 
Accounts payable and accrued liabilities30,886 31,958 
Short-term borrowings and current maturities of long-term debt11,371 4,274 
Unearned revenues2,572 3,355 
Other current liabilities27,294 27,072 
Total current liabilities104,670 99,054 
Long-term debt, less current maturities63,727 58,263 
Deferred income taxes3,631 3,021 
Other liabilities14,794 14,463 
Total liabilities186,822 174,801 
Redeemable noncontrolling interests4,558 4,498 
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding
— — 
Common stock, $0.01 par value - 3,000 shares authorized; 921 and 924 issued and outstanding
9 9 
Additional paid-in capital373 — 
Retained earnings92,400 95,774 
Accumulated other comprehensive loss(3,423)(7,027)
Nonredeemable noncontrolling interests
5,317 5,665 
Total equity94,676 94,421 
Total liabilities, redeemable noncontrolling interests and equity$286,056 $273,720 
1
UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
 Three Months Ended
June 30,		Six Months Ended
June 30,
(in millions, except per share data)2024202320242023
Revenues:
Premiums$76,897 $72,474 $154,885 $145,260 
Products12,211 10,651 24,120 20,918 
Services8,750 8,663 17,638 16,743 
Investment and other income997 1,115 2,008 1,913 
Total revenues98,855 92,903 198,651 184,834 
Operating costs:
Medical costs65,458 60,268 131,193 120,113 
Operating costs13,162 13,809 27,239 27,434 
Cost of products sold11,340 9,748 22,396 19,153 
Depreciation and amortization1,020 1,021 2,017 1,991 
Total operating costs90,980 84,846 182,845 168,691 
Earnings from operations7,875 8,057 15,806 16,143 
Interest expense(985)(828)(1,829)(1,582)
Loss on sale of subsidiary and subsidiaries held for sale(1,225)— (8,311)— 
Earnings before income taxes5,665 7,229 5,666 14,561 
Provision for income taxes(1,244)(1,572)(2,466)(3,130)
Net earnings4,421 5,657 3,200 11,431 
Earnings attributable to noncontrolling interests(205)(183)(393)(346)
Net earnings attributable to UnitedHealth Group common shareholders$4,216 $5,474 $2,807 $11,085 
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic$4.58 $5.89 $3.05 $11.91 
Diluted$4.54 $5.82 $3.02 $11.77 
Basic weighted-average number of common shares outstanding921 930 921 931 
Dilutive effect of common share equivalents7 10 8 11 
Diluted weighted-average number of common shares outstanding928 940 929 942 
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents8 7 7 6 
2
UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
 Three Months Ended
June 30,		Six Months Ended
June 30,
(in millions)2024202320242023
Net earnings$4,421 $5,657 $3,200 $11,431 
Other comprehensive income (loss):
Gross unrealized (losses) gains on investment securities during the period(75)(431)(365)209 
Income tax effect17 99 85 (48)
Total unrealized (losses) gains, net of tax(58)(332)(280)161 
Gross reclassification adjustment for net realized gains included in net earnings(26)(47)(58)(34)
Income tax effect6 11 13 8 
Total reclassification adjustment, net of tax
(20)(36)(45)(26)
Foreign currency translation gains (losses) 8 267 (285)608 
Reclassification adjustment for translation losses included in net earnings86 — 4,214 — 
Total foreign currency translation gains94 267 3,929 608 
Other comprehensive income (loss)16 (101)3,604 743 
Comprehensive income4,437 5,556 6,804 12,174 
Comprehensive income attributable to noncontrolling interests(205)(183)(393)(346)
Comprehensive income attributable to UnitedHealth Group common shareholders$4,232 $5,373 $6,411 $11,828 
3
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossNonredeemable Noncontrolling InterestsTotal
Equity
Three months ended June 30,
(in millions)		SharesAmountNet Unrealized (Losses) Gains on InvestmentsForeign Currency Translation (Losses) Gains
Balance at March 31, 2024920 $9 $— $90,118 $(2,218)$(1,221)$5,682 $92,370 
Net earnings4,216 158 4,374 
Other comprehensive (loss) income(78)94 16 
Issuances of common stock, and related tax effects
1 — 196 196 
Share-based compensation
210 210 
Common share repurchases— — 3 1 4 
Cash dividends paid on common shares ($2.10 per share)
(1,935)(1,935)
Redeemable noncontrolling interests fair value and other adjustments
(36)(36)
Acquisition and other adjustments of nonredeemable noncontrolling interests
(338)(338)
Distribution to nonredeemable noncontrolling interests
(185)(185)
Balance at June 30, 2024921 $9 $373 $92,400 $(2,296)$(1,127)$5,317 $94,676 
Balance at March 31, 2023932 $9 $— $88,852 $(2,275)$(5,274)$4,509 $85,821 
Net earnings
5,474 139 5,613 
Other comprehensive (loss) income(368)267 (101)
Issuances of common stock, and related tax effects
1 — 218 218 
Share-based compensation
232 232 
Common share repurchases(6)— (442)(2,585)(3,027)
Cash dividends paid on common shares ($1.88 per share)
(1,747)(1,747)
Redeemable noncontrolling interests fair value and other adjustments
(8)(8)
Acquisition and other adjustments of nonredeemable noncontrolling interests478 478 
Distribution to nonredeemable noncontrolling interests
(111)(111)
Balance at June 30, 2023927 $9 $— $89,994 $(2,643)$(5,007)$5,015 $87,368 







4
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossNonredeemable Noncontrolling InterestsTotal
Equity
Six months ended June 30,
(in millions)		SharesAmountNet Unrealized (Losses) Gains on InvestmentsForeign Currency Translation (Losses) Gains
Balance at January 1, 2024924 $9 $— $95,774 $(1,971)$(5,056)$5,665 $94,421 
Net earnings2,807 307 3,114 
Other comprehensive (loss) income(325)3,929 3,604 
Issuances of common stock, and related tax effects3 — 438 438 
Share-based compensation562 562 
Common share repurchases(6)— (571)(2,517)(3,088)
Cash dividends paid on common shares ($3.98 per share)
(3,664)(3,664)
Redeemable noncontrolling interests fair value and other adjustments(56)(56)
Acquisition and other adjustments of nonredeemable noncontrolling interests(319)(319)
Distribution to nonredeemable noncontrolling interests(336)(336)
Balance at June 30, 2024921 $9 $373 $92,400 $(2,296)$(1,127)$5,317 $94,676 
Balance at January 1, 2023934 $9 $— $86,156 $(2,778)$(5,615)$3,678 $81,450 
Net earnings
11,085 252 11,337 
Other comprehensive income135 608 743 
Issuances of common stock, and related tax effects
3 — 568 568 
Share-based compensation
598 598 
Common share repurchases(10)— (1,075)(3,963)(5,038)
Cash dividends paid on common shares ($3.53 per share)
(3,284)(3,284)
Redeemable noncontrolling interests fair value and other adjustments
(91)(91)
Acquisition and other adjustments of nonredeemable noncontrolling interests1,297 1,297 
Distribution to nonredeemable noncontrolling interests
(212)(212)
Balance at June 30, 2023927 $9 $— $89,994 $(2,643)$(5,007)$5,015 $87,368 
5
UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 Six Months Ended
June 30,
(in millions)20242023
Operating activities
Net earnings$3,200 $11,431 
Noncash items:
Depreciation and amortization2,017 1,991 
Deferred income taxes(358)(482)
Share-based compensation594 604 
Loss on sale of subsidiary and subsidiaries held for sale8,311 — 
Other, net459 (91)
Net change in other operating items, net of effects from acquisitions, dispositions and changes in AARP balances:
Accounts receivable(2,471)197 
Other assets(4,121)(2,001)
Medical costs payable777 2,408 
Accounts payable and other liabilities36 1,547 
Unearned revenues(554)11,755 
Cash flows from operating activities7,890 27,359 
Investing activities
Purchases of investments(10,130)(9,225)
Sales of investments5,288 3,188 
Maturities of investments4,621 4,463 
Cash paid for acquisitions, net of cash assumed(3,031)(8,161)
Purchases of property, equipment and capitalized software(1,596)(1,589)
Loans to providers - cyberattack(8,100)— 
Other, net(809)(424)
Cash flows used for investing activities(13,757)(11,748)
Financing activities
Common share repurchases(3,072)(5,000)
Cash dividends paid(3,664)(3,284)
Proceeds from common stock issuances744 628 
Repayments of long-term debt(1,750)(2,125)
Proceeds from short-term borrowings, net8,615 3,426 
Proceeds from issuance of long-term debt5,925 6,394 
Customer funds administered990 4,069 
Other, net(753)(1,377)
Cash flows from financing activities7,035 2,731 
Effect of exchange rate changes on cash and cash equivalents(44)106 
Increase in cash and cash equivalents, including cash within businesses held for sale1,124 18,448 
Less: cash within businesses held for sale(265)— 
Net increase in cash and cash equivalents859 18,448 
Cash and cash equivalents, beginning of period25,427 23,365 
Cash and cash equivalents, end of period$26,286 $41,813 
6
UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1.    Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC (2023 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenues - Products and Services
As of June 30, 2024 and December 31, 2023, accounts receivable related to products and services were $9.0 billion and $8.6 billion, respectively. As of June 30, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $14.0 billion, of which approximately half is expected to be recognized in the next three years.
7
2.    Investments
A summary of debt securities by major security type is as follows:
(in millions)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
June 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations$5,007 $— $(264)$4,743 
State and municipal obligations7,299 4 (397)6,906 
Corporate obligations23,193 14 (1,222)21,985 
U.S. agency mortgage-backed securities9,320 3 (899)8,424 
Non-U.S. agency mortgage-backed securities2,894 — (218)2,676 
Total debt securities - available-for-sale47,713 21 (3,000)44,734 
Debt securities - held-to-maturity:
U.S. government and agency obligations413 — (4)409 
State and municipal obligations28 — (3)25 
Corporate obligations124 — — 124 
Total debt securities - held-to-maturity565 — (7)558 
Total debt securities$48,278 $21 $(3,007)$45,292 
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations$4,674 $3 $(234)$4,443 
State and municipal obligations7,636 39 (322)7,353 
Corporate obligations23,136 67 (1,186)22,017 
U.S. agency mortgage-backed securities8,982 22 (708)8,296 
Non-U.S. agency mortgage-backed securities3,023 3 (240)2,786 
Total debt securities - available-for-sale47,451 134 (2,690)44,895 
Debt securities - held-to-maturity:
U.S. government and agency obligations506 1 (6)501 
State and municipal obligations28 — (2)26 
Corporate obligations69 — — 69 
Total debt securities - held-to-maturity603 1 (8)596 
Total debt securities$48,054 $135 $(2,698)$45,491 
The Company held $4.2 billion and $4.9 billion of equity securities as of June 30, 2024 and December 31, 2023, respectively. The Company’s investments in equity securities primarily consist of venture investments and employee savings plan related investments. Additionally, the Company’s investments included $1.7 billion and $1.4 billion of equity method investments primarily in operating businesses in the health care sector as of June 30, 2024 and December 31, 2023, respectively. The allowance for credit losses on held-to-maturity securities at June 30, 2024 and December 31, 2023 was not material.
8
The amortized cost and fair value of debt securities as of June 30, 2024, by contractual maturity, were as follows:
Available-for-SaleHeld-to-Maturity
(in millions)Amortized
Cost		Fair
Value		Amortized
Cost		Fair
Value
Due in one year or less$5,172 $5,137 $363 $362 
Due after one year through five years14,656 14,021 171 168 
Due after five years through ten years10,930 10,044 14 13 
Due after ten years4,741 4,432 17 15 
U.S. agency mortgage-backed securities9,320 8,424 — — 
Non-U.S. agency mortgage-backed securities2,894 2,676 — — 
Total debt securities$47,713 $44,734 $565 $558 
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 Less Than 12 Months12 Months or Greater Total
(in millions)Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
June 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,187 $(9)$2,773 $(255)$3,960 $(264)
State and municipal obligations1,942 (30)4,584 (367)6,526 (397)
Corporate obligations5,334 (49)13,570 (1,173)18,904 (1,222)
U.S. agency mortgage-backed securities2,511 (45)5,757 (854)8,268 (899)
Non-U.S. agency mortgage-backed securities
403 (4)2,157 (214)2,560 (218)
Total debt securities - available-for-sale$11,377 $(137)$28,841 $(2,863)$40,218 $(3,000)
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,270 $(7)$2,077 $(227)$3,347 $(234)
State and municipal obligations907 (7)4,063 (315)4,970 (322)
Corporate obligations1,826 (17)14,696 (1,169)16,522 (1,186)
U.S. agency mortgage-backed securities1,337 (12)5,069 (696)6,406 (708)
Non-U.S. agency mortgage-backed securities
279 (6)2,202 (234)2,481 (240)
Total debt securities - available-for-sale$5,619 $(49)$28,107 $(2,641)$33,726 $(2,690)
The Company’s unrealized losses from debt securities as of June 30, 2024 were generated from approximately 33,000 positions out of a total of 40,000 positions. The Company believes that it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of June 30, 2024, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at June 30, 2024 and December 31, 2023 was not material.
9
3.    Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair and Carrying
Value
June 30, 2024
Cash and cash equivalents$26,070$216$—$26,286
Debt securities - available-for-sale:
U.S. government and agency obligations4,571172—4,743
State and municipal obligations—6,906—6,906
Corporate obligations2021,76819721,985
U.S. agency mortgage-backed securities—8,424—8,424
Non-U.S. agency mortgage-backed securities—2,676—2,676
Total debt securities - available-for-sale4,59139,94619744,734
Equity securities1,70116691,786
Assets under management 1,4141,8931073,414
Total assets at fair value$33,776$42,071$373$76,220
Percentage of total assets at fair value44 %55 %1 %100 %
December 31, 2023
Cash and cash equivalents$25,345$82$—$25,427
Debt securities - available-for-sale:
U.S. government and agency obligations4,167276—4,443
State and municipal obligations—7,353—7,353
Corporate obligations1521,80020222,017
U.S. agency mortgage-backed securities—8,296—8,296
Non-U.S. agency mortgage-backed securities—2,786—2,786
Total debt securities - available-for-sale4,18240,51120244,895
Equity securities2,46816692,553
Assets under management 1,5052,1401103,755
Total assets at fair value$33,500$42,749$381$76,630
Percentage of total assets at fair value44 %55 %1 %100 %
There were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2024 or 2023.
10
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair
Value		Total Carrying Value
June 30, 2024
Debt securities - held-to-maturity$531 $27 $— $558 $565 
Long-term debt and other financing obligations$— $61,144 $— $61,144 $65,186 
December 31, 2023
Debt securities - held-to-maturity$524 $72 $— $596 $603 
Long-term debt and other financing obligations$— $59,851 $— $59,851 $61,449 
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets and liabilities within our South American operations held for sale as of June 30, 2024 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information and market conditions. There were no other significant fair value adjustments for assets and liabilities recorded during the six months ended June 30, 2024 or 2023.
4.    Medical Costs Payable
The following table shows the components of the change in medical costs payable for the six months ended June 30:
(in millions)20242023
Medical costs payable, beginning of period$32,395 $29,056 
Acquisitions (dispositions), net(687)1 
Reported medical costs:
Current year131,583 120,773 
Prior years(390)(660)
Total reported medical costs131,193 120,113 
Medical payments:
Payments for current year
(102,288)(91,621)
Payments for prior years(27,887)(25,602)
Total medical payments(130,175)(117,223)
Less: medical costs payable included within businesses held for sale(179)— 
Medical costs payable, end of period$32,547 $31,947 
For the six months ended June 30, 2024 and 2023, prior years’ medical cost reserve development included no individual factors that were significant. Medical costs payable included reserves for claims incurred by consumers but not yet reported to the Company of $23.6 billion and $22.3 billion at June 30, 2024 and December 31, 2023, respectively.
11
5.    Short-Term Borrowings and Long-Term Debt
In March 2024, the Company issued $6.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
4.600% notes due April 2027
$500 
4.700% notes due April 2029
400 
4.900% notes due April 2031
1,000 
5.000% notes due April 2034
1,250 
5.375% Notes due April 2054
1,750 
5.500% Notes due April 2064
1,100 
In July 2024, the Company issued $12.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
Floating rate notes due July 2026
$500 
4.750% notes due July 2026
650 
4.800% notes due January 2030
1,250 
4.950% notes due January 2032
1,500 
5.150% notes due July 2034
2,000 
5.500% notes due July 2044
1,500 
5.625% notes due July 2054
2,750 
5.750% notes due July 2064
1,850 
As of June 30, 2024, the Company had $9.9 billion of commercial paper outstanding, with a weighted-average annual interest rate of 5.4%.
In May 2024, the Company entered into an additional $3 billion 364-day revolving bank credit facility and a $5 billion 364-day delayed draw term loan. As of June 30, 2024 no amount had been drawn on any of the bank credit facilities.
For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
6.    Shareholders’ Equity
Share Repurchase Program
In June 2024, the Company’s Board of Directors amended the Company’s share repurchase program to authorize the repurchase of up to 35 million shares of Common Stock, in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. As of June 30, 2024, the Company had 44 million shares remaining available under its share repurchase authorization.
Dividends
In June 2024, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $8.40 compared to $7.52 per share, which the Company had paid since June 2023. Declaration and payment of future quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions change.
The following table provides details of the Company’s dividend payments during the six months ended June 30, 2024:
Payment DateAmount per ShareTotal Amount Paid
(in millions)
March 19$1.88 $1,729 
June 252.10 1,935 
12
7.    Commitments and Contingencies
Pending Transactions
As of June 30, 2024, the Company had entered into transaction agreements in the health care sector, subject to regulatory approval and/or other customary closing conditions. The total anticipated consideration required for these transactions, excluding the payoff of acquired indebtedness, was approximately $6 billion. In July, 2024, the Company completed transactions in the health care sector for total consideration of approximately $10 billion.
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau (CFPB), the Defense Contract Audit Agency and other governmental authorities. Similarly, the Company’s international businesses are also subject to investigations, audits and reviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and investigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters and no assurance as to whether its business, financial condition or results of operations will be materially adversely affected. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
13
8.    Disposition and Held for Sale
On February 6, 2024, the Company completed the sale of its Brazil operations. During the six months ended June 30, 2024, the Company recorded a loss of $7.1 billion within the Condensed Consolidated Statement of Operations, of which $4.1 billion related to the impact of cumulative foreign currency translation losses previously included in accumulated other comprehensive loss.
In the second quarter of 2024, the Company initiated a plan to sell its remaining South American operations. The sales are expected to close within a year, subject to regulatory and other customary closing conditions. The Company determined that the businesses are classified as held for sale. Assets and liabilities held for sale have been included within prepaid and other current assets and other current liabilities on the Condensed Consolidated Balance Sheet, respectively. In the second quarter of 2024, the Company recorded a loss of $1.2 billion within the Condensed Consolidated Statements of Operations, of which $867 million related to the impact of cumulative foreign currency translation losses.
The assets and liabilities of the Brazil and held for sale disposal groups as of the date of the sale and as of June 30, 2024, respectively, were as follows:
(in millions)Brazil
Disposition		Businesses
Held for Sale
Assets
Cash and cash equivalents$778 $265 
Accounts receivable and other current assets515 608 
Long-term investments788 39 
Property, equipment and capitalized software1,052 633 
Deferred tax assets1,035 — 
Goodwill and other intangible assets317 445 
Other long-term assets439 246 
Remeasurement of assets of businesses held for sale to fair value less cost to sell(1)
— (1,225)
Total assets$4,924 $1,011 
Liabilities
Medical costs payable$701 $179 
Accounts payable and other current liabilities834 378 
Other long-term liabilities136 524 
Total liabilities$1,671 $1,081 
(1)      Includes the effect of $867 million of cumulative foreign currency translation losses and $52 million of noncontrolling interests.
14
9.    Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
The following tables present reportable segment financial information:
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Three Months Ended June 30, 2024
Revenues - unaffiliated customers:
Premiums$70,950 $5,947 $— $— $— $5,947 $— $76,897 
Products— 62 41 12,108 — 12,211 — 12,211 
Services2,388 4,083 1,405 874 — 6,362 — 8,750 
Total revenues - unaffiliated customers
73,338 10,092 1,446 12,982 — 24,520 — 97,858 
Total revenues - affiliated customers
— 16,576 3,070 19,373 (1,129)37,890 (37,890)— 
Investment and other income
528 382 27 60 — 469 — 997 
Total revenues$73,866 $27,050 $4,543 $32,415 $(1,129)$62,879 $(37,890)$98,855 
Earnings from operations$4,004 $1,919 $546 $1,406 $— $3,871 $— $7,875 
Interest expense— — — — — — (985)(985)
Loss on sale of subsidiary and subsidiaries held for sale(1,225)— — — — — — (1,225)
Earnings before income taxes
$2,779 $1,919 $546 $1,406 $— $3,871 $(985)$5,665 
Three Months Ended June 30, 2023
Revenues - unaffiliated customers:
Premiums$67,047 $5,427 $— $— $— $5,427 $— $72,474 
Products— 51 39 10,561 — 10,651 — 10,651 
Services2,584 3,541 1,995 543 — 6,079 — 8,663 
Total revenues - unaffiliated customers
69,631 9,019 2,034 11,104 — 22,157 — 91,788 
Total revenues - affiliated customers
— 14,454 2,615 17,496 (893)33,672 (33,672)— 
Investment and other income
600 444 25 46 — 515 — 1,115 
Total revenues$70,231 $23,917 $4,674 $28,646 $(893)$56,344 $(33,672)$92,903 
Earnings from operations$4,358 $1,525 $968 $1,206 $— $3,699 $— $8,057 
Interest expense— — — — — — (828)(828)
Earnings before income taxes
$4,358 $1,525 $968 $1,206 $— $3,699 $(828)$7,229 
15
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Six Months Ended June 30, 2024
Revenues - unaffiliated customers:
Premiums$143,243 $11,642 $— $— $— $11,642 $— $154,885 
Products— 121 82 23,917 — 24,120 — 24,120 
Services4,917 8,053 3,107 1,561 — 12,721 — 17,638 
Total revenues - unaffiliated customers
148,160 19,816 3,189 25,478 — 48,483 — 196,643 
Total revenues - affiliated customers
— 33,193 5,801 37,654 (2,145)74,503 (74,503)— 
Investment and other income
1,063 772 55 118 — 945 — 2,008 
Total revenues$149,223 $53,781 $9,045 $63,250 $(2,145)$123,931 $(74,503)$198,651 
Earnings from operations$8,399 $3,818 $1,036 $2,553 $— $7,407 $— $15,806 
Interest expense— — — — — — (1,829)(1,829)
Loss on sale of subsidiary and subsidiaries held for sale(8,311)— — — — — — (8,311)
Earnings before income taxes
$88 $3,818 $1,036 $2,553 $— $7,407 $(1,829)$5,666 
Six Months Ended June 30, 2023
Revenues - unaffiliated customers:
Premiums$134,505 $10,755 $— $— $— $10,755 $— $145,260 
Products— 95 79 20,744 — 20,918 — 20,918 
Services5,139 6,630 3,921 1,053 — 11,604 — 16,743 
Total revenues - unaffiliated customers
139,644 17,480 4,000 21,797 — 43,277 — 182,921 
Total revenues - affiliated customers
— 28,720 5,125 34,175 (1,752)66,268 (66,268)— 
Investment and other income
1,055 721 45 92 — 858 — 1,913 
Total revenues$140,699 $46,921 $9,170 $56,064 $(1,752)$110,403 $(66,268)$184,834 
Earnings from operations$8,701 $3,301 $1,875 $2,266 $— $7,442 $— $16,143 
Interest expense— — — — — — (1,582)(1,582)
Earnings before income taxes
$8,701 $3,301 $1,875 $2,266 $— $7,442 $(1,582)$14,561 
16
ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2023 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2023 10-K and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments:
•Optum Health;
•Optum Insight;
•Optum Rx; and
•UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2023 10-K and additional information on our segments can be found in this Item 2 and in Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Change Healthcare Cyberattack
As previously announced, on February 21, 2024, we identified that cybercrime threat actors had gained access to certain Change Healthcare information technology systems. Upon detection of this outside threat, we isolated the impacted systems to protect our partners and customers.
We have made substantial progress in mitigating the impact to consumers and care providers of the unprecedented cyberattack on the U.S. health system and have restored the majority of the affected Change Healthcare services. To support care providers, we accelerated funding and provided interest-free loans of more than $9 billion through June 30, 2024. For the three and six months ended June 30, 2024, we incurred $776 million and $1.4 billion of direct response costs, respectively, including network restoration and increased medical care expenditures, as we suspended some care management activities to help care providers with their workflow processes. Optum Insight also experienced estimated business disruption impacts of $334 million and $613 million for the three and six months ended June 30, 2024, respectively, reflecting lost revenue while maintaining full readiness of the affected Change Healthcare services. We expect to continue to incur direct response costs and experience business disruption impacts over the remainder of the year, including costs to continue to restore Change Healthcare’s services.
Based upon our ongoing review of the impacted data, we have found files containing protected health information (PHI) or personally identifiable information (PII), which cover a substantial proportion of people in America. In June 2024, Change Healthcare gave public notice of the breach under HIPAA and began notifying affected customer entities in June and individuals in late July. The investigation of impacted data is ongoing. It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations.
17
Business Trends
Our businesses participate in the United States and certain other international health markets. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs, including medical cost trends, inflation and labor market dynamics. We frequently evaluate and adjust our approach in each of the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments. We will continue seeking to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs.
Government programs in the community and senior sector tend to receive lower rates of increase than the commercial market due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs. As expected and contemplated in our benefits design, we have continued to observe increased care patterns, primarily related to outpatient procedures for seniors, which may continue in future periods. We endeavor to mitigate those increases by engaging physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve quality, affordable care.
As a result of the Change Healthcare cyberattack, we incurred medical costs related to the impact of the temporary suspension of some care management activities, impacting our UnitedHealthcare and Optum Health businesses, to help care providers with their workflow processes. Early in the second quarter we resumed these activities. For the three and six months June 30, 2024, medical costs related to the temporary suspension of some care management activities were $290 million and $630 million, respectively.
Medicaid Redeterminations. Medicaid redeterminations have continued to impact the number of people served through our Medicaid offerings, partially offset by an increase in consumers served through our commercial offerings as we endeavor to ensure that people and families have continued access to care.
Regulatory Trends and Uncertainties
Medicare Advantage Rates. Medicare Advantage rate notices over the years have at times resulted in industry base rates well below the industry forward medical trend. For example, the Final Notices for 2024 and 2025 rates resulted in an industry base rate decrease, both well short of an increasing industry forward medical cost trend, creating continued pressure in the Medicare Advantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient’s health status and care resource needs, will result in reduced funding and potentially benefits for people, especially those with some of the greatest health and social challenges.
As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans.
18
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select second quarter 2024 year-over-year operating comparisons to second quarter 2023 and other financial results.
•Consolidated revenues grew 6%, UnitedHealthcare revenues grew 5% and Optum revenues grew 12%.
•UnitedHealthcare served 1.6 million more people domestically, driven by growth in commercial offerings, partially offset by the impact of Medicaid redeterminations.
•Consolidated earnings from operations of $7.9 billion compared to $8.1 billion last year, impacted by the Change Healthcare cyberattack.
•Diluted earnings per common share was $4.54, impacted by the loss on our South American subsidiaries held for sale and the Change Healthcare cyberattack.
•Cash flows from operations for the six months ended June 30, 2024 were $7.9 billion.
RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data)Three Months Ended
June 30,		Increase/
(Decrease)		Six Months Ended
June 30,		Increase/
(Decrease)
202420232024 vs. 2023202420232024 vs. 2023
Revenues:
Premiums$76,897 $72,474$4,423 6 %$154,885 $145,260$9,625 7 %
Products12,211 10,6511,560 15 24,120 20,9183,202 15 
Services8,750 8,66387 1 17,638 16,743895 5 
Investment and other income997 1,115(118)(11)2,008 1,91395 5 
Total revenues98,855 92,9035,952 6 198,651 184,83413,817 7 
Operating costs:
Medical costs65,458 60,2685,190 9 131,193 120,11311,080 9 
Operating costs13,162 13,809(647)(5)27,239 27,434(195)(1)
Cost of products sold11,340 9,7481,592 16 22,396 19,1533,243 17 
Depreciation and amortization1,020 1,021(1)— 2,017 1,99126 1 
Total operating costs90,980 84,8466,134 7 182,845 168,69114,154 8 
Earnings from operations7,875 8,057(182)(2)15,806 16,143(337)(2)
Interest expense(985)(828)(157)19 (1,829)(1,582)(247)16 
Loss on sale of subsidiary and subsidiaries held for sale(1,225)—(1,225)nm(8,311)—(8,311)nm
Earnings before income taxes5,665 7,229(1,564)(22)5,666 14,561(8,895)(61)
Provision for income taxes(1,244)(1,572)328 (21)(2,466)(3,130)664 (21)
Net earnings4,421 5,657(1,236)(22)3,200 11,431(8,231)(72)
Earnings attributable to noncontrolling interests(205)(183)(22)12 (393)(346)(47)14 
Net earnings attributable to UnitedHealth Group common shareholders$4,216 $5,474$(1,258)(23)$2,807 $11,085$(8,278)(75)
Diluted earnings per share attributable to UnitedHealth Group common shareholders $4.54 $5.82$(1.28)$3.02 $11.77$(8.75)
Medical care ratio (a)85.1 %83.2%1.9 %84.7 %82.7%2.0 %
Operating cost ratio13.3 14.9(1.6)13.7 14.8(1.1)
Operating margin8.0 8.7(0.7)8.0 8.7(0.7)
Tax rate22.021.70.3 43.521.522.0 
Net earnings margin (b)4.3 5.9(1.6)1.4 6.0(4.6)
Return on equity (c)19.2%26.8%(7.6)6.4%27.5%(21.1)
nm = not meaningful
(a)Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b)Net earnings margin attributable to UnitedHealth Group shareholders.
(c)Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the end of each of the quarters in the year presented.
19
2024 RESULTS OF OPERATIONS COMPARED TO 2023 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
The increases in revenues were primarily driven by growth in Optum Rx and Optum Health, growth across our UnitedHealthcare domestic offerings and pricing trends, partially offset by decreased UnitedHealthcare international revenue due to the sale of our Brazil operations.
Medical Costs and MCR
Medical costs increased primarily due to growth in people served through Medicare Advantage, those with higher acuity needs and domestic commercial offerings. The MCR increased as a result of the revenue effects of the Medicare funding reductions, incremental medical costs for accommodations made to care providers as a result of the Change Healthcare cyberattack, South American impacts and decreased favorable reserve development.
Operating Cost Ratio
The operating cost ratio decreased primarily due to operating cost management, partially offset by the impact of our direct response efforts to the Change Healthcare cyberattack and investments to support future growth.
Loss on Sale of Subsidiary and Subsidiaries Held for Sale
On February 6, 2024, the Company completed the sale of its Brazil operations. During the six months ended June 30, 2024, we recorded a loss of $7.1 billion, of which $4.1 billion related to the impact of cumulative foreign currency translation losses previously included in accumulated other comprehensive loss.
In the second quarter of 2024, the Company initiated a plan to sell its remaining South American operations, which were classified as held for sale as of June 30, 2024. As a result, the Company recorded a loss of $1.2 billion, of which $867 million related to the impact of cumulative foreign currency translation losses.
Reportable Segments
See Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also allow management and investors to evaluate and understand business mix, including the level and scope of services provided to people, and pricing trends when comparing the metrics to revenue by segment.
20
The following table presents a summary of the reportable segment financial information:
 Three Months Ended
June 30,		Increase/
(Decrease)		Six Months Ended
June 30,		Increase/
(Decrease)
(in millions, except percentages)202420232024 vs. 2023202420232024 vs. 2023
Revenues
UnitedHealthcare$73,866 $70,231$3,6355 %$149,223$140,699$8,524 6 %
Optum Health27,050 23,9173,13313 53,78146,9216,860 15 
Optum Insight4,543 4,674(131)(3)9,0459,170(125)(1)
Optum Rx32,415 28,6463,76913 63,25056,0647,186 13 
Optum eliminations(1,129)(893)(236)26 (2,145)(1,752)(393)22 
Optum62,879 56,3446,53512 123,931110,40313,528 12 
Eliminations(37,890)(33,672)(4,218)13 (74,503)(66,268)(8,235)12 
Consolidated revenues$98,855 $92,903$5,9526 %$198,651$184,834$13,817 7 %
Earnings from operations
UnitedHealthcare$4,004 $4,358$(354)(8)%$8,399$8,701$(302)(3)%
Optum Health1,919 1,52539426 3,8183,301517 16 
Optum Insight546 968(422)(44)1,0361,875(839)(45)
Optum Rx1,406 1,20620017 2,5532,266287 13 
Optum3,871 3,6991725 7,4077,442(35)— 
Consolidated earnings from operations$7,875 $8,057$(182)(2)%$15,806$16,143$(337)(2)%
Operating margin
UnitedHealthcare5.4 %6.2 %(0.8)%5.6 %6.2 %(0.6)%
Optum Health7.1 6.4 0.7 7.1 7.0 0.1 
Optum Insight12.0 20.7 (8.7)11.5 20.4 (8.9)
Optum Rx4.3 4.2 0.1 4.0 4.0 — 
Optum6.2 6.6 (0.4)6.0 6.7 (0.7)
Consolidated operating margin8.0 %8.7 %(0.7)%8.0 %8.7 %(0.7)%
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
 Three Months Ended
June 30,		Increase/
(Decrease)		Six Months Ended
June 30,		Increase/
(Decrease)
(in millions, except percentages)202420232024 vs. 2023202420232024 vs. 2023
UnitedHealthcare Employer & Individual - Domestic$18,646 $16,759 $1,887 11 %$36,485 $33,303 $3,182 10 %
UnitedHealthcare Employer & Individual - Global591 2,325 (1,734)(75)2,123 4,488 (2,365)(53)
UnitedHealthcare Employer & Individual - Total19,237 19,084 153 1 38,608 37,791 817 2 
UnitedHealthcare Medicare & Retirement34,904 32,440 2,464 8 70,390 65,446 4,944 8 
UnitedHealthcare Community & State19,725 18,707 1,018 5 40,225 37,462 2,763 7 
Total UnitedHealthcare revenues$73,866 $70,231 $3,635 5 %$149,223 $140,699 $8,524 6 %
21
The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment and funding arrangement:
June 30,Increase/(Decrease)
(in thousands, except percentages)202420232024 vs. 2023
Commercial - Domestic:
Risk-based8,735 8,035 700 9 %
Fee-based20,835 19,140 1,695 9 
Total Commercial - Domestic29,570 27,175 2,395 9 
Medicare Advantage7,770 7,590 180 2 
Medicaid7,410 8,355 (945)(11)
Medicare Supplement (Standardized)4,335 4,330 5 — 
Total Community and Senior19,515 20,275 (760)(4)
Total UnitedHealthcare - Domestic Medical49,085 47,450 1,635 3 
Commercial - Global1,330 5,385 (4,055)(75)
Total UnitedHealthcare - Medical50,415 52,835 (2,420)(5)%
Supplemental Data:
Medicare Part D stand-alone3,065 3,355 (290)(9)%
UnitedHealthcare’s revenues increased due to growth in the number of people served through Medicare Advantage, domestic commercial offerings and those with higher acuity needs, partially offset by decreased people served globally due to the sale of our Brazil operations and Medicaid offerings due to continued redeterminations. Earnings from operations increased due to the factors impacting revenue, partially offset by Medicare Advantage funding reductions and incremental medical costs for accommodations to support care providers as a result of the Change Healthcare cyberattack.
Optum
Total revenues increased due to growth at Optum Rx and Optum Health. Earnings from operations increased for the three months ended June 30, 2024 and were consistent for the six months ended June 30, 2024, with growth at Optum Rx and Optum Health offset by the impacts of the Change Healthcare cyberattack. The results by segment were as follows:
Optum Health
Revenues at Optum Health increased primarily due to organic growth in patients served under value-based care arrangements. Earnings from operations increased due to cost management initiatives, partially offset by costs associated with serving newly added patients under value-based care arrangements. For the six months ended June 30, 2024, earnings from operations increases were also partially offset by incremental medical costs for accommodations to support care providers as a result of the Change Healthcare cyberattack. Optum Health served approximately 104 million people and 103 million people as of June 30, 2024 and June 30, 2023, respectively.
Optum Insight
Revenues at Optum Insight decreased due the business disruption impacts from the Change Healthcare cyberattack, partially offset by growth in technology services. Earnings from operations decreased primarily due to the business disruption impacts and direct response costs related to the Change Healthcare cyberattack.
Optum Rx
Revenues and earnings from operations at Optum Rx increased due to higher script volumes from both new clients and growth in existing clients and growth in pharmacy services. Optum Rx fulfilled 399 million and 381 million adjusted scripts in the second quarters of 2024 and 2023, respectively.
22
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
 Six Months Ended June 30,Increase/(Decrease)
(in millions)202420232024 vs. 2023
Sources of cash:
Cash provided by operating activities$7,890 $27,359 $(19,469)
Issuances of short-term borrowings and long-term debt, net of repayments12,790 7,695 5,095 
Proceeds from common stock issuances744 628 116 
Customer funds administered990 4,069 (3,079)
Total sources of cash22,414 39,751 (17,337)
Uses of cash:
Common stock repurchases(3,072)(5,000)1,928 
Cash paid for acquisitions, net of cash assumed(3,031)(8,161)5,130 
Purchases of investments, net of sales and maturities (221)(1,574)1,353 
Purchases of property, equipment and capitalized software(1,596)(1,589)(7)
Cash dividends paid(3,664)(3,284)(380)
Loans to providers - cyberattack(8,100)— (8,100)
Other(1,562)(1,801)239 
Total uses of cash(21,246)(21,409)163 
Effect of exchange rate changes on cash and cash equivalents(44)106 (150)
Increase in cash and cash equivalents, including cash classified within assets held for sale$1,124 $18,448 $(17,324)
Less: net increase in cash classified within assets held for sale(265)— (265)
Net increase in cash and cash equivalents$859 $18,448 $(17,589)
2024 Cash Flows Compared to 2023 Cash Flows
Decreased cash flows provided by operating activities were primarily driven by the receipt of the July CMS premium payment of $11.8 billion in June 2023 and Change Healthcare cyberattack response actions, including the acceleration of provider payments. Other significant changes in sources or uses of cash year-over-year included decreased cash paid for acquisitions, increased net issuances of short-term borrowings and long-term debt, decreased share repurchases and net purchases of investments, offset by loans to care providers in response to the Change Healthcare cyberattack and decreased customer funds administered.
Financial Condition
As of June 30, 2024, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $75.2 billion included approximately $26.3 billion of cash and cash equivalents (of which $4.1 billion was available for general corporate use), $44.7 billion of debt securities and $4.2 billion of investments in equity securities. Given the significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-average duration of 4.0 years and a weighted-average credit rating of “Double A” as of June 30, 2024. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.

23
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2023 was disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2023 10-K. During the six months ended June 30, 2024, there were no material changes to this previously disclosed information outside the ordinary course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2023 10-K.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. As of June 30, 2024, our debt to debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was approximately 43%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2023 10-K.
Credit Ratings. Our credit ratings as of June 30, 2024 were as follows:
  
Moody’sS&P GlobalFitchA.M. Best
 RatingsOutlookRatingsOutlookRatingsOutlookRatingsOutlook
Senior unsecured debtA2StableA+StableAStableAStable
Commercial paperP-1n/aA-1n/aF1n/aAMB-1+n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the six months ended June 30, 2024, we repurchased approximately 6 million shares at an average price of $505.46 per share. In June 2024, our Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of Common Stock, in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. As of June 30, 2024, we had Board of Directors’ authorization to purchase up to 44 million shares of our common stock. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.
Dividends. In June 2024, our Board of Directors increased our quarterly cash dividend to an annual rate of $8.40 compared to $7.52 per share, which we had paid since June 2023. For more information on our dividend, see Note 6 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Pending Transactions. As of June 30, 2024, the Company had entered into transaction agreements in the health care sector, subject to regulatory approval and/or other customary closing conditions. The total anticipated consideration required for these transactions, excluding the payoff of acquired indebtedness, was approximately $6 billion. In July, 2024, the Company completed transactions in the health care sector for total consideration of approximately $10 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2023 10-K.

24
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2023 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2023 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties associated with the continuing sale of operations in South America; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
25
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of June 30, 2024 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):
June 30, 2024
Increase (Decrease) in Market Interest RateInvestment
Income Per
Annum		Interest
Expense Per
Annum		Fair Value of
Financial Assets		Fair Value of
Financial Liabilities
2 %$701 $592 $(3,634)$(7,939)
1351 296 (1,869)(4,329)
(1)(351)(279)1,959 5,239 
(2)(701)(557)3,989 11,641 
Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.
ITEM 4.    CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2024. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2024.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.    LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A.    RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2023 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2023 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2023 10-K.
26
ITEM 2.    UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2024, the Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs), in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. There is no established expiration date for the program. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.
There were no repurchases of the Company’s Common Stock during the three months ended June 30, 2024. As of June 30, 2024, the Company had 44 million shares remaining available under its share repurchase authorization.
ITEM 5.    OTHER INFORMATION
Trading Arrangements
During the quarter ended June 30, 2024, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.
ITEM 6.    EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
 ________________
*Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.
27
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
UNITEDHEALTH GROUP INCORPORATED
 
/s/ ANDREW WITTY
Chief Executive Officer
(principal executive officer)		Dated:August 9, 2024
Andrew Witty  
/s/ JOHN REX
President and Chief Financial Officer
(principal financial officer)		Dated:August 9, 2024
John Rex  
/s/ THOMAS ROOS
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)		Dated:August 9, 2024
Thomas Roos  
28

EXHIBIT 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
Certification of Principal Executive Officer

 I, Andrew P. Witty, certify that:

1.I have reviewed this report on Form 10-Q of UnitedHealth Group Incorporated (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 
August 9, 2024
/s/ ANDREW P. WITTY
 Andrew P. Witty
Chief Executive Officer



Certification of Principal Financial Officer

I, John F. Rex, certify that:

1.I have reviewed this report on Form 10-Q of UnitedHealth Group Incorporated (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


 
August 9, 2024
/s/ JOHN F. REX
 John F. Rex
President and Chief Financial Officer



EXHIBIT 32.1
CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Certification of Principal Executive Officer
In connection with the report of UnitedHealth Group Incorporated (the “Company”) on Form 10-Q for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Andrew P. Witty, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
August 9, 2024
/s/ ANDREW P. WITTY
 Andrew P. Witty
Chief Executive Officer
Certification of Principal Financial Officer
In connection with the report of UnitedHealth Group Incorporated (the “Company”) on Form 10-Q for the period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John F. Rex, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


 
August 9, 2024
/s/ JOHN F. REX
 John F. Rex
President and Chief Financial Officer

v3.24.2.u1
Document and Entity Information Document - shares
 6 Months Ended
Jun. 30, 2024
Jul. 31, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2024  
Document Transition Report false  
Entity File Number 1-10864  
Entitiy Registrant Name UnitedHealth Group Incorporated  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 41-1321939  
Entity Address, Address Line One 9900 Bren Road East  
Entity Address, City or Town Minnetonka,  
Entity Address, State or Province MN  
Entity Address, Postal Zip Code 55343  
Other Address, Address line one 655 New York Avenue NW  
Other Entity Address, City or Town Washington,  
Other Entity Address, State or Province DC  
Other Entity Address, Postal Zip Code 20001  
City Area Code (800)  
Local Phone Number 328-5979  
Title of 12(b) Security Common Stock, $.01 par value  
Trading Symbol UNH  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entitiy Central Index Key 0000731766  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   923,418,150
v3.24.2.u1
Condensed Consolidated Balance Sheets - USD ($)
shares in Millions, $ in Millions
Jun. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 26,286 $ 25,427
Short-term investments 5,037 4,201
Accounts receivable, net 23,115 21,276
Other current receivables, net 26,762 17,694
Assets under management 3,414 3,755
Prepaid expenses and other current assets 7,424 6,084
Total current assets 92,038 78,437
Long-term investments 46,113 47,609
Property, equipment and capitalized software, net 9,801 11,450
Goodwill 105,436 103,732
Other intangible assets, net 14,729 15,194
Other assets 17,939 17,298
Total assets 286,056 273,720
Current liabilities:    
Medical costs payable 32,547 32,395
Accounts payable and accrued liabilities 30,886 31,958
Short-term borrowings and current maturities of long-term debt 11,371 4,274
Unearned revenues 2,572 3,355
Other current liabilities 27,294 27,072
Total current liabilities 104,670 99,054
Long-term debt, less current maturities 63,727 58,263
Deferred income taxes 3,631 3,021
Other liabilities 14,794 14,463
Total liabilities 186,822 174,801
Commitments and contingencies (Note 7)
Redeemable noncontrolling interests 4,558 4,498
Equity:    
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding 0 0
Common stock, $0.01 par value - 3,000 shares authorized; 921 and 924 issued and outstanding 9 9
Additional paid-in capital 373 0
Retained earnings 92,400 95,774
Accumulated other comprehensive loss (3,423) (7,027)
Nonredeemable noncontrolling interests 5,317 5,665
Total equity 94,676 94,421
Total liabilities, redeemable noncontrolling interests and equity $ 286,056 $ 273,720
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10 10
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 3,000 3,000
Common stock, shares issued 921 924
Common stock, shares outstanding 921 924
v3.24.2.u1
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues:        
Premiums $ 76,897 $ 72,474 $ 154,885 $ 145,260
Investment and other income 997 1,115 2,008 1,913
Total revenues 98,855 92,903 198,651 184,834
Operating costs:        
Medical Costs 65,458 60,268 131,193 120,113
Operating costs 13,162 13,809 27,239 27,434
Cost of products sold 11,340 9,748 22,396 19,153
Depreciation and amortization 1,020 1,021 2,017 1,991
Total operating costs 90,980 84,846 182,845 168,691
Earnings from operations 7,875 8,057 15,806 16,143
Interest expense (985) (828) (1,829) (1,582)
Loss on sale of subsidiary and subsidiaries held for sale (1,225) 0 (8,311) 0
Earnings before income taxes 5,665 7,229 5,666 14,561
Provision for income taxes (1,244) (1,572) (2,466) (3,130)
Net earnings 4,421 5,657 3,200 11,431
Earnings attributable to noncontrolling interests (205) (183) (393) (346)
Net earnings attributable to UnitedHealth Group common shareholders $ 4,216 $ 5,474 $ 2,807 $ 11,085
Earnings per share attributable to UnitedHealth Group common shareholders:        
Basic $ 4.58 $ 5.89 $ 3.05 $ 11.91
Diluted $ 4.54 $ 5.82 $ 3.02 $ 11.77
Basic weighted-average number of common shares outstanding 921 930 921 931
Dilutive effect of common share equivalents 7 10 8 11
Diluted weighted-average number of common shares outstanding 928 940 929 942
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 8 7 7 6
Products        
Revenues:        
Revenue from Products and Services $ 12,211 $ 10,651 $ 24,120 $ 20,918
Services        
Revenues:        
Revenue from Products and Services $ 8,750 $ 8,663 $ 17,638 $ 16,743
v3.24.2.u1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Net earnings $ 4,421 $ 5,657 $ 3,200 $ 11,431
Other comprehensive income (loss):        
Gross unrealized (losses) gains on investment securities during the period (75) (431) (365) 209
Income tax effect 17 99 85 (48)
Total unrealized (losses) gains, net of tax (58) (332) (280) 161
Gross reclassification adjustment for net realized gains included in net earnings (26) (47) (58) (34)
Income tax effect 6 11 13 8
Total reclassification adjustment, net of tax (20) (36) (45) (26)
Foreign currency translation gains (losses) 8 267 (285) 608
Reclassification adjustment for translation losses included in net earnings 86 0 4,214 0
Total foreign currency translation gains 94 267 3,929 608
Other comprehensive income (loss) 16 (101) 3,604 743
Comprehensive income 4,437 5,556 6,804 12,174
Comprehensive income attributable to noncontrolling interests (205) (183) (393) (346)
Comprehensive income attributable to UnitedHealth Group common shareholders $ 4,232 $ 5,373 $ 6,411 $ 11,828
v3.24.2.u1
Condensed Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock [Member]
Additional Paid-In Capital [Member]
Retained Earnings [Member]
Net Unrealized (Losses) Gains on Investments [Member]
Foreign Currency Translation (Losses) Gains [Member]
Nonredeemable Noncontrolling Interests [Member]
Balance at Dec. 31, 2022 $ 81,450 $ 9 $ 0 $ 86,156 $ (2,778) $ (5,615) $ 3,678
Balance (in shares) at Dec. 31, 2022   934          
Net earnings attributable to UnitedHealth Group common shareholders 11,085     11,085      
Net earnings attributable to nonredeemable noncontrolling interest             252
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest 11,337            
Other comprehensive income (loss) 743       135 608  
Issuances of common stock, and related tax effects (in shares)   3          
Issuances of common stock, and related tax effects 568 $ 0 568        
Share-based compensation 598   598        
Common share repurchases (in shares)   (10)          
Common share repurchases (5,038) $ 0 (1,075) (3,963)      
Cash dividends paid on common shares (3,284)     (3,284)      
Redeemable noncontrolling interests fair value and other adjustments (91)   (91)        
Acquisition and other adjustments of nonredeemable noncontrolling interests 1,297           1,297
Distribution to nonredeemable noncontrolling interests (212)           (212)
Balance at Jun. 30, 2023 $ 87,368 $ 9 0 89,994 (2,643) (5,007) 5,015
Balance (in shares) at Jun. 30, 2023   927          
Common Stock, Dividends, Per Share, Cash Paid $ 3.53            
Balance at Mar. 31, 2023 $ 85,821 $ 9 0 88,852 (2,275) (5,274) 4,509
Balance (in shares) at Mar. 31, 2023   932          
Net earnings attributable to UnitedHealth Group common shareholders 5,474     5,474      
Net earnings attributable to nonredeemable noncontrolling interest             139
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest 5,613            
Other comprehensive income (loss) (101)       (368) 267  
Issuances of common stock, and related tax effects (in shares)   1          
Issuances of common stock, and related tax effects 218 $ 0 218        
Share-based compensation 232   232        
Common share repurchases (in shares)   (6)          
Common share repurchases (3,027) $ 0 (442) (2,585)      
Cash dividends paid on common shares (1,747)     (1,747)      
Redeemable noncontrolling interests fair value and other adjustments (8)   (8)        
Acquisition and other adjustments of nonredeemable noncontrolling interests 478           478
Distribution to nonredeemable noncontrolling interests (111)           (111)
Balance at Jun. 30, 2023 $ 87,368 $ 9 0 89,994 (2,643) (5,007) 5,015
Balance (in shares) at Jun. 30, 2023   927          
Common Stock, Dividends, Per Share, Cash Paid $ 1.88            
Balance at Dec. 31, 2023 $ 94,421 $ 9 0 95,774 (1,971) (5,056) 5,665
Balance (in shares) at Dec. 31, 2023 924 924          
Net earnings attributable to UnitedHealth Group common shareholders $ 2,807     2,807      
Net earnings attributable to nonredeemable noncontrolling interest             307
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest 3,114            
Other comprehensive income (loss) 3,604       (325) 3,929  
Issuances of common stock, and related tax effects (in shares)   3          
Issuances of common stock, and related tax effects 438 $ 0 438        
Share-based compensation 562   562        
Common share repurchases (in shares)   (6)          
Common share repurchases (3,088) $ 0 (571) (2,517)      
Cash dividends paid on common shares (3,664)     (3,664)      
Redeemable noncontrolling interests fair value and other adjustments (56)   (56)        
Acquisition and other adjustments of nonredeemable noncontrolling interests (319)           (319)
Distribution to nonredeemable noncontrolling interests (336)           (336)
Balance at Jun. 30, 2024 $ 94,676 $ 9 373 92,400 (2,296) (1,127) 5,317
Balance (in shares) at Jun. 30, 2024 921 921          
Common Stock, Dividends, Per Share, Cash Paid $ 3.98            
Balance at Mar. 31, 2024 $ 92,370 $ 9 0 90,118 (2,218) (1,221) 5,682
Balance (in shares) at Mar. 31, 2024   920          
Net earnings attributable to UnitedHealth Group common shareholders 4,216     4,216      
Net earnings attributable to nonredeemable noncontrolling interest             158
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest 4,374            
Other comprehensive income (loss) 16       (78) 94  
Issuances of common stock, and related tax effects (in shares)   1          
Issuances of common stock, and related tax effects 196 $ 0 196        
Share-based compensation 210   210        
Common share repurchases (in shares)   0          
Common share repurchases 4 $ 0 3 1      
Cash dividends paid on common shares (1,935)     (1,935)      
Redeemable noncontrolling interests fair value and other adjustments (36)   (36)        
Acquisition and other adjustments of nonredeemable noncontrolling interests (338)           (338)
Distribution to nonredeemable noncontrolling interests (185)           (185)
Balance at Jun. 30, 2024 $ 94,676 $ 9 $ 373 $ 92,400 $ (2,296) $ (1,127) $ 5,317
Balance (in shares) at Jun. 30, 2024 921 921          
Common Stock, Dividends, Per Share, Cash Paid $ 2.10            
v3.24.2.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Operating activities    
Net earnings $ 3,200 $ 11,431
Noncash items:    
Depreciation and amortization 2,017 1,991
Deferred income taxes (358) (482)
Share-based compensation 594 604
Loss on sale of subsidiary and subsidiaries held for sale (8,311) 0
Other, net 459 (91)
Net change in other operating items, net of effects from acquisitions, dispositions and changes in AARP balances:    
Accounts receivable (2,471) 197
Other assets (4,121) (2,001)
Medical costs payable 777 2,408
Accounts payable and other liabilities 36 1,547
Unearned revenues (554) 11,755
Cash flows from operating activities 7,890 27,359
Investing activities    
Purchases of investments (10,130) (9,225)
Sales of investments 5,288 3,188
Maturities of investments 4,621 4,463
Cash paid for acquisitions, net of cash assumed (3,031) (8,161)
Purchases of property, equipment and capitalized software (1,596) (1,589)
Loans to providers - cyberattack (8,100) 0
Other, net (809) (424)
Cash flows used for investing activities (13,757) (11,748)
Financing activities    
Common share repurchases (3,072) (5,000)
Cash dividends paid (3,664) (3,284)
Proceeds from common stock issuances 744 628
Repayments of long-term debt (1,750) (2,125)
Proceeds from short-term borrowings, net 8,615 3,426
Proceeds from issuance of long-term debt 5,925 6,394
Customer funds administered 990 4,069
Other, net (753) (1,377)
Cash flows from financing activities 7,035 2,731
Effect of exchange rate changes on cash and cash equivalents (44) 106
Increase in cash and cash equivalents, including cash within businesses held for sale 1,124 18,448
Less: cash within businesses held for sale (265) 0
Net increase in cash and cash equivalents 859 18,448
Cash and cash equivalents, beginning of period 25,427 23,365
Cash and cash equivalents, end of period $ 26,286 $ 41,813
v3.24.2.u1
Basis of Presentation (Notes)
 6 Months Ended
Jun. 30, 2024
Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC (2023 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenues - Products and Services
As of June 30, 2024 and December 31, 2023, accounts receivable related to products and services were $9.0 billion and $8.6 billion, respectively. As of June 30, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $14.0 billion, of which approximately half is expected to be recognized in the next three years.
v3.24.2.u1
Investments (Notes)
 6 Months Ended
Jun. 30, 2024
Investments [Abstract]  
Investments [Text Block] Investments
A summary of debt securities by major security type is as follows:
(in millions)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
June 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations$5,007 $— $(264)$4,743 
State and municipal obligations7,299 4 (397)6,906 
Corporate obligations23,193 14 (1,222)21,985 
U.S. agency mortgage-backed securities9,320 3 (899)8,424 
Non-U.S. agency mortgage-backed securities2,894 — (218)2,676 
Total debt securities - available-for-sale47,713 21 (3,000)44,734 
Debt securities - held-to-maturity:
U.S. government and agency obligations413 — (4)409 
State and municipal obligations28 — (3)25 
Corporate obligations124 — — 124 
Total debt securities - held-to-maturity565 — (7)558 
Total debt securities$48,278 $21 $(3,007)$45,292 
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations$4,674 $3 $(234)$4,443 
State and municipal obligations7,636 39 (322)7,353 
Corporate obligations23,136 67 (1,186)22,017 
U.S. agency mortgage-backed securities8,982 22 (708)8,296 
Non-U.S. agency mortgage-backed securities3,023 3 (240)2,786 
Total debt securities - available-for-sale47,451 134 (2,690)44,895 
Debt securities - held-to-maturity:
U.S. government and agency obligations506 1 (6)501 
State and municipal obligations28 — (2)26 
Corporate obligations69 — — 69 
Total debt securities - held-to-maturity603 1 (8)596 
Total debt securities$48,054 $135 $(2,698)$45,491 
The Company held $4.2 billion and $4.9 billion of equity securities as of June 30, 2024 and December 31, 2023, respectively. The Company’s investments in equity securities primarily consist of venture investments and employee savings plan related investments. Additionally, the Company’s investments included $1.7 billion and $1.4 billion of equity method investments primarily in operating businesses in the health care sector as of June 30, 2024 and December 31, 2023, respectively. The allowance for credit losses on held-to-maturity securities at June 30, 2024 and December 31, 2023 was not material.
The amortized cost and fair value of debt securities as of June 30, 2024, by contractual maturity, were as follows:
Available-for-SaleHeld-to-Maturity
(in millions)Amortized
Cost		Fair
Value		Amortized
Cost		Fair
Value
Due in one year or less$5,172 $5,137 $363 $362 
Due after one year through five years14,656 14,021 171 168 
Due after five years through ten years10,930 10,044 14 13 
Due after ten years4,741 4,432 17 15 
U.S. agency mortgage-backed securities9,320 8,424 — — 
Non-U.S. agency mortgage-backed securities2,894 2,676 — — 
Total debt securities$47,713 $44,734 $565 $558 
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 Less Than 12 Months12 Months or Greater Total
(in millions)Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
June 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,187 $(9)$2,773 $(255)$3,960 $(264)
State and municipal obligations1,942 (30)4,584 (367)6,526 (397)
Corporate obligations5,334 (49)13,570 (1,173)18,904 (1,222)
U.S. agency mortgage-backed securities2,511 (45)5,757 (854)8,268 (899)
Non-U.S. agency mortgage-backed securities
403 (4)2,157 (214)2,560 (218)
Total debt securities - available-for-sale$11,377 $(137)$28,841 $(2,863)$40,218 $(3,000)
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,270 $(7)$2,077 $(227)$3,347 $(234)
State and municipal obligations907 (7)4,063 (315)4,970 (322)
Corporate obligations1,826 (17)14,696 (1,169)16,522 (1,186)
U.S. agency mortgage-backed securities1,337 (12)5,069 (696)6,406 (708)
Non-U.S. agency mortgage-backed securities
279 (6)2,202 (234)2,481 (240)
Total debt securities - available-for-sale$5,619 $(49)$28,107 $(2,641)$33,726 $(2,690)
The Company’s unrealized losses from debt securities as of June 30, 2024 were generated from approximately 33,000 positions out of a total of 40,000 positions. The Company believes that it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of June 30, 2024, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at June 30, 2024 and December 31, 2023 was not material.
v3.24.2.u1
Fair Value (Notes)
 6 Months Ended
Jun. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value [Text Block] Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair and Carrying
Value
June 30, 2024
Cash and cash equivalents$26,070$216$—$26,286
Debt securities - available-for-sale:
U.S. government and agency obligations4,571172—4,743
State and municipal obligations—6,906—6,906
Corporate obligations2021,76819721,985
U.S. agency mortgage-backed securities—8,424—8,424
Non-U.S. agency mortgage-backed securities—2,676—2,676
Total debt securities - available-for-sale4,59139,94619744,734
Equity securities1,70116691,786
Assets under management 1,4141,8931073,414
Total assets at fair value$33,776$42,071$373$76,220
Percentage of total assets at fair value44 %55 %1 %100 %
December 31, 2023
Cash and cash equivalents$25,345$82$—$25,427
Debt securities - available-for-sale:
U.S. government and agency obligations4,167276—4,443
State and municipal obligations—7,353—7,353
Corporate obligations1521,80020222,017
U.S. agency mortgage-backed securities—8,296—8,296
Non-U.S. agency mortgage-backed securities—2,786—2,786
Total debt securities - available-for-sale4,18240,51120244,895
Equity securities2,46816692,553
Assets under management 1,5052,1401103,755
Total assets at fair value$33,500$42,749$381$76,630
Percentage of total assets at fair value44 %55 %1 %100 %
There were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2024 or 2023.
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair
Value		Total Carrying Value
June 30, 2024
Debt securities - held-to-maturity$531 $27 $— $558 $565 
Long-term debt and other financing obligations$— $61,144 $— $61,144 $65,186 
December 31, 2023
Debt securities - held-to-maturity$524 $72 $— $596 $603 
Long-term debt and other financing obligations$— $59,851 $— $59,851 $61,449 
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets and liabilities within our South American operations held for sale as of June 30, 2024 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information and market conditions. There were no other significant fair value adjustments for assets and liabilities recorded during the six months ended June 30, 2024 or 2023.
v3.24.2.u1
Medical Costs Payable (Notes)
 6 Months Ended
Jun. 30, 2024
Insurance [Abstract]  
Short-Duration Insurance and Deposit Contracts Medical Costs Payable
The following table shows the components of the change in medical costs payable for the six months ended June 30:
(in millions)20242023
Medical costs payable, beginning of period$32,395 $29,056 
Acquisitions (dispositions), net(687)1 
Reported medical costs:
Current year131,583 120,773 
Prior years(390)(660)
Total reported medical costs131,193 120,113 
Medical payments:
Payments for current year
(102,288)(91,621)
Payments for prior years(27,887)(25,602)
Total medical payments(130,175)(117,223)
Less: medical costs payable included within businesses held for sale(179)— 
Medical costs payable, end of period$32,547 $31,947 
For the six months ended June 30, 2024 and 2023, prior years’ medical cost reserve development included no individual factors that were significant. Medical costs payable included reserves for claims incurred by consumers but not yet reported to the Company of $23.6 billion and $22.3 billion at June 30, 2024 and December 31, 2023, respectively.
v3.24.2.u1
Short-Term Borrowings and Long-Term Debt (Notes)
 6 Months Ended
Jun. 30, 2024
Debt Disclosure [Abstract]  
Debt Disclosure Short-Term Borrowings and Long-Term Debt
In March 2024, the Company issued $6.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
4.600% notes due April 2027
$500 
4.700% notes due April 2029
400 
4.900% notes due April 2031
1,000 
5.000% notes due April 2034
1,250 
5.375% Notes due April 2054
1,750 
5.500% Notes due April 2064
1,100 
In July 2024, the Company issued $12.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
Floating rate notes due July 2026
$500 
4.750% notes due July 2026
650 
4.800% notes due January 2030
1,250 
4.950% notes due January 2032
1,500 
5.150% notes due July 2034
2,000 
5.500% notes due July 2044
1,500 
5.625% notes due July 2054
2,750 
5.750% notes due July 2064
1,850 
As of June 30, 2024, the Company had $9.9 billion of commercial paper outstanding, with a weighted-average annual interest rate of 5.4%.
In May 2024, the Company entered into an additional $3 billion 364-day revolving bank credit facility and a $5 billion 364-day delayed draw term loan. As of June 30, 2024 no amount had been drawn on any of the bank credit facilities.
For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
v3.24.2.u1
Shareholders' Equity (Notes)
 6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
Stockholders' Equity Note Disclosure Shareholders’ Equity
Share Repurchase Program
In June 2024, the Company’s Board of Directors amended the Company’s share repurchase program to authorize the repurchase of up to 35 million shares of Common Stock, in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. As of June 30, 2024, the Company had 44 million shares remaining available under its share repurchase authorization.
Dividends
In June 2024, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $8.40 compared to $7.52 per share, which the Company had paid since June 2023. Declaration and payment of future quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions change.
The following table provides details of the Company’s dividend payments during the six months ended June 30, 2024:
Payment DateAmount per ShareTotal Amount Paid
(in millions)
March 19$1.88 $1,729 
June 252.10 1,935 
v3.24.2.u1
Commitments and Contingencies (Notes)
 6 Months Ended
Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies
Pending Transactions
As of June 30, 2024, the Company had entered into transaction agreements in the health care sector, subject to regulatory approval and/or other customary closing conditions. The total anticipated consideration required for these transactions, excluding the payoff of acquired indebtedness, was approximately $6 billion. In July, 2024, the Company completed transactions in the health care sector for total consideration of approximately $10 billion.
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office of Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau (CFPB), the Defense Contract Audit Agency and other governmental authorities. Similarly, the Company’s international businesses are also subject to investigations, audits and reviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and investigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters and no assurance as to whether its business, financial condition or results of operations will be materially adversely affected. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
v3.24.2.u1
Disposition and Held for Sale (Notes)
 6 Months Ended
Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Dispositions and Held for Sale [Text Block] Disposition and Held for Sale
On February 6, 2024, the Company completed the sale of its Brazil operations. During the six months ended June 30, 2024, the Company recorded a loss of $7.1 billion within the Condensed Consolidated Statement of Operations, of which $4.1 billion related to the impact of cumulative foreign currency translation losses previously included in accumulated other comprehensive loss.
In the second quarter of 2024, the Company initiated a plan to sell its remaining South American operations. The sales are expected to close within a year, subject to regulatory and other customary closing conditions. The Company determined that the businesses are classified as held for sale. Assets and liabilities held for sale have been included within prepaid and other current assets and other current liabilities on the Condensed Consolidated Balance Sheet, respectively. In the second quarter of 2024, the Company recorded a loss of $1.2 billion within the Condensed Consolidated Statements of Operations, of which $867 million related to the impact of cumulative foreign currency translation losses.
The assets and liabilities of the Brazil and held for sale disposal groups as of the date of the sale and as of June 30, 2024, respectively, were as follows:
(in millions)Brazil
Disposition		Businesses
Held for Sale
Assets
Cash and cash equivalents$778 $265 
Accounts receivable and other current assets515 608 
Long-term investments788 39 
Property, equipment and capitalized software1,052 633 
Deferred tax assets1,035 — 
Goodwill and other intangible assets317 445 
Other long-term assets439 246 
Remeasurement of assets of businesses held for sale to fair value less cost to sell(1)
— (1,225)
Total assets$4,924 $1,011 
Liabilities
Medical costs payable$701 $179 
Accounts payable and other current liabilities834 378 
Other long-term liabilities136 524 
Total liabilities$1,671 $1,081 
(1)      Includes the effect of $867 million of cumulative foreign currency translation losses and $52 million of noncontrolling interests.
v3.24.2.u1
Segment Financial Information (Notes)
 6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Segment Reporting Disclosure Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
The following tables present reportable segment financial information:
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Three Months Ended June 30, 2024
Revenues - unaffiliated customers:
Premiums$70,950 $5,947 $— $— $— $5,947 $— $76,897 
Products— 62 41 12,108 — 12,211 — 12,211 
Services2,388 4,083 1,405 874 — 6,362 — 8,750 
Total revenues - unaffiliated customers
73,338 10,092 1,446 12,982 — 24,520 — 97,858 
Total revenues - affiliated customers
— 16,576 3,070 19,373 (1,129)37,890 (37,890)— 
Investment and other income
528 382 27 60 — 469 — 997 
Total revenues$73,866 $27,050 $4,543 $32,415 $(1,129)$62,879 $(37,890)$98,855 
Earnings from operations$4,004 $1,919 $546 $1,406 $— $3,871 $— $7,875 
Interest expense— — — — — — (985)(985)
Loss on sale of subsidiary and subsidiaries held for sale(1,225)— — — — — — (1,225)
Earnings before income taxes
$2,779 $1,919 $546 $1,406 $— $3,871 $(985)$5,665 
Three Months Ended June 30, 2023
Revenues - unaffiliated customers:
Premiums$67,047 $5,427 $— $— $— $5,427 $— $72,474 
Products— 51 39 10,561 — 10,651 — 10,651 
Services2,584 3,541 1,995 543 — 6,079 — 8,663 
Total revenues - unaffiliated customers
69,631 9,019 2,034 11,104 — 22,157 — 91,788 
Total revenues - affiliated customers
— 14,454 2,615 17,496 (893)33,672 (33,672)— 
Investment and other income
600 444 25 46 — 515 — 1,115 
Total revenues$70,231 $23,917 $4,674 $28,646 $(893)$56,344 $(33,672)$92,903 
Earnings from operations$4,358 $1,525 $968 $1,206 $— $3,699 $— $8,057 
Interest expense— — — — — — (828)(828)
Earnings before income taxes
$4,358 $1,525 $968 $1,206 $— $3,699 $(828)$7,229 
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Six Months Ended June 30, 2024
Revenues - unaffiliated customers:
Premiums$143,243 $11,642 $— $— $— $11,642 $— $154,885 
Products— 121 82 23,917 — 24,120 — 24,120 
Services4,917 8,053 3,107 1,561 — 12,721 — 17,638 
Total revenues - unaffiliated customers
148,160 19,816 3,189 25,478 — 48,483 — 196,643 
Total revenues - affiliated customers
— 33,193 5,801 37,654 (2,145)74,503 (74,503)— 
Investment and other income
1,063 772 55 118 — 945 — 2,008 
Total revenues$149,223 $53,781 $9,045 $63,250 $(2,145)$123,931 $(74,503)$198,651 
Earnings from operations$8,399 $3,818 $1,036 $2,553 $— $7,407 $— $15,806 
Interest expense— — — — — — (1,829)(1,829)
Loss on sale of subsidiary and subsidiaries held for sale(8,311)— — — — — — (8,311)
Earnings before income taxes
$88 $3,818 $1,036 $2,553 $— $7,407 $(1,829)$5,666 
Six Months Ended June 30, 2023
Revenues - unaffiliated customers:
Premiums$134,505 $10,755 $— $— $— $10,755 $— $145,260 
Products— 95 79 20,744 — 20,918 — 20,918 
Services5,139 6,630 3,921 1,053 — 11,604 — 16,743 
Total revenues - unaffiliated customers
139,644 17,480 4,000 21,797 — 43,277 — 182,921 
Total revenues - affiliated customers
— 28,720 5,125 34,175 (1,752)66,268 (66,268)— 
Investment and other income
1,055 721 45 92 — 858 — 1,913 
Total revenues$140,699 $46,921 $9,170 $56,064 $(1,752)$110,403 $(66,268)$184,834 
Earnings from operations$8,701 $3,301 $1,875 $2,266 $— $7,442 $— $16,143 
Interest expense— — — — — — (1,582)(1,582)
Earnings before income taxes
$8,701 $3,301 $1,875 $2,266 $— $7,442 $(1,582)$14,561 
v3.24.2.u1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Pay vs Performance Disclosure        
Net earnings attributable to UnitedHealth Group common shareholders $ 4,216 $ 5,474 $ 2,807 $ 11,085
v3.24.2.u1
Insider Trading Arrangements
 3 Months Ended
Jun. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.2.u1
Basis of Presentation (Policies)
 6 Months Ended
Jun. 30, 2024
Basis of presentation [Abstract]  
Basis of Accounting, Policy [Policy Text Block] The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC (2023 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates, Policy [Policy Text Block]
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenue [Policy Text Block] As of June 30, 2024 and December 31, 2023, accounts receivable related to products and services were $9.0 billion and $8.6 billion, respectively. As of June 30, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $14.0 billion, of which approximately half is expected to be recognized in the next three years.
v3.24.2.u1
Investments (Policies)
 6 Months Ended
Jun. 30, 2024
Investments [Abstract]  
Investment, Policy [Policy Text Block] At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of June 30, 2024, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary.
v3.24.2.u1
Investments (Tables)
 6 Months Ended
Jun. 30, 2024
Short-Term and Long-Term Investments [Table Text Block]
A summary of debt securities by major security type is as follows:
(in millions)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
June 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations$5,007 $— $(264)$4,743 
State and municipal obligations7,299 4 (397)6,906 
Corporate obligations23,193 14 (1,222)21,985 
U.S. agency mortgage-backed securities9,320 3 (899)8,424 
Non-U.S. agency mortgage-backed securities2,894 — (218)2,676 
Total debt securities - available-for-sale47,713 21 (3,000)44,734 
Debt securities - held-to-maturity:
U.S. government and agency obligations413 — (4)409 
State and municipal obligations28 — (3)25 
Corporate obligations124 — — 124 
Total debt securities - held-to-maturity565 — (7)558 
Total debt securities$48,278 $21 $(3,007)$45,292 
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations$4,674 $3 $(234)$4,443 
State and municipal obligations7,636 39 (322)7,353 
Corporate obligations23,136 67 (1,186)22,017 
U.S. agency mortgage-backed securities8,982 22 (708)8,296 
Non-U.S. agency mortgage-backed securities3,023 3 (240)2,786 
Total debt securities - available-for-sale47,451 134 (2,690)44,895 
Debt securities - held-to-maturity:
U.S. government and agency obligations506 1 (6)501 
State and municipal obligations28 — (2)26 
Corporate obligations69 — — 69 
Total debt securities - held-to-maturity603 1 (8)596 
Total debt securities$48,054 $135 $(2,698)$45,491 
Investments by Contractual Maturity [Table Text Block]
The amortized cost and fair value of debt securities as of June 30, 2024, by contractual maturity, were as follows:
Available-for-SaleHeld-to-Maturity
(in millions)Amortized
Cost		Fair
Value		Amortized
Cost		Fair
Value
Due in one year or less$5,172 $5,137 $363 $362 
Due after one year through five years14,656 14,021 171 168 
Due after five years through ten years10,930 10,044 14 13 
Due after ten years4,741 4,432 17 15 
U.S. agency mortgage-backed securities9,320 8,424 — — 
Non-U.S. agency mortgage-backed securities2,894 2,676 — — 
Total debt securities$47,713 $44,734 $565 $558 
Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 Less Than 12 Months12 Months or Greater Total
(in millions)Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
June 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,187 $(9)$2,773 $(255)$3,960 $(264)
State and municipal obligations1,942 (30)4,584 (367)6,526 (397)
Corporate obligations5,334 (49)13,570 (1,173)18,904 (1,222)
U.S. agency mortgage-backed securities2,511 (45)5,757 (854)8,268 (899)
Non-U.S. agency mortgage-backed securities
403 (4)2,157 (214)2,560 (218)
Total debt securities - available-for-sale$11,377 $(137)$28,841 $(2,863)$40,218 $(3,000)
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,270 $(7)$2,077 $(227)$3,347 $(234)
State and municipal obligations907 (7)4,063 (315)4,970 (322)
Corporate obligations1,826 (17)14,696 (1,169)16,522 (1,186)
U.S. agency mortgage-backed securities1,337 (12)5,069 (696)6,406 (708)
Non-U.S. agency mortgage-backed securities
279 (6)2,202 (234)2,481 (240)
Total debt securities - available-for-sale$5,619 $(49)$28,107 $(2,641)$33,726 $(2,690)
v3.24.2.u1
Fair Value (Tables)
 6 Months Ended
Jun. 30, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block]
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair and Carrying
Value
June 30, 2024
Cash and cash equivalents$26,070$216$—$26,286
Debt securities - available-for-sale:
U.S. government and agency obligations4,571172—4,743
State and municipal obligations—6,906—6,906
Corporate obligations2021,76819721,985
U.S. agency mortgage-backed securities—8,424—8,424
Non-U.S. agency mortgage-backed securities—2,676—2,676
Total debt securities - available-for-sale4,59139,94619744,734
Equity securities1,70116691,786
Assets under management 1,4141,8931073,414
Total assets at fair value$33,776$42,071$373$76,220
Percentage of total assets at fair value44 %55 %1 %100 %
December 31, 2023
Cash and cash equivalents$25,345$82$—$25,427
Debt securities - available-for-sale:
U.S. government and agency obligations4,167276—4,443
State and municipal obligations—7,353—7,353
Corporate obligations1521,80020222,017
U.S. agency mortgage-backed securities—8,296—8,296
Non-U.S. agency mortgage-backed securities—2,786—2,786
Total debt securities - available-for-sale4,18240,51120244,895
Equity securities2,46816692,553
Assets under management 1,5052,1401103,755
Total assets at fair value$33,500$42,749$381$76,630
Percentage of total assets at fair value44 %55 %1 %100 %
Fair Value Measurements, Nonrecurring [Table Text Block]
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair
Value		Total Carrying Value
June 30, 2024
Debt securities - held-to-maturity$531 $27 $— $558 $565 
Long-term debt and other financing obligations$— $61,144 $— $61,144 $65,186 
December 31, 2023
Debt securities - held-to-maturity$524 $72 $— $596 $603 
Long-term debt and other financing obligations$— $59,851 $— $59,851 $61,449 
v3.24.2.u1
Medical Costs Payable (Tables)
 6 Months Ended
Jun. 30, 2024
Insurance [Abstract]  
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense
The following table shows the components of the change in medical costs payable for the six months ended June 30:
(in millions)20242023
Medical costs payable, beginning of period$32,395 $29,056 
Acquisitions (dispositions), net(687)1 
Reported medical costs:
Current year131,583 120,773 
Prior years(390)(660)
Total reported medical costs131,193 120,113 
Medical payments:
Payments for current year
(102,288)(91,621)
Payments for prior years(27,887)(25,602)
Total medical payments(130,175)(117,223)
Less: medical costs payable included within businesses held for sale(179)— 
Medical costs payable, end of period$32,547 $31,947 
v3.24.2.u1
Short-Term Borrowings and Long-Term Debt (Tables)
 6 Months Ended
Jun. 30, 2024
Debt Instrument [Line Items]  
Long-Term Debt [Table Text Block]
In March 2024, the Company issued $6.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
4.600% notes due April 2027
$500 
4.700% notes due April 2029
400 
4.900% notes due April 2031
1,000 
5.000% notes due April 2034
1,250 
5.375% Notes due April 2054
1,750 
5.500% Notes due April 2064
1,100 
In July 2024, the Company issued $12.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
Floating rate notes due July 2026
$500 
4.750% notes due July 2026
650 
4.800% notes due January 2030
1,250 
4.950% notes due January 2032
1,500 
5.150% notes due July 2034
2,000 
5.500% notes due July 2044
1,500 
5.625% notes due July 2054
2,750 
5.750% notes due July 2064
1,850 
v3.24.2.u1
Stockholders' Equity (Tables)
 6 Months Ended
Jun. 30, 2024
Equity [Abstract]  
Dividends Declared
The following table provides details of the Company’s dividend payments during the six months ended June 30, 2024:
Payment DateAmount per ShareTotal Amount Paid
(in millions)
March 19$1.88 $1,729 
June 252.10 1,935 
v3.24.2.u1
Disposition and Held for Sale (Tables)
Feb. 06, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Disposed Assets and Liabilities [Table Text Block]
The assets and liabilities of the Brazil and held for sale disposal groups as of the date of the sale and as of June 30, 2024, respectively, were as follows:
(in millions)Brazil
Disposition		Businesses
Held for Sale
Assets
Cash and cash equivalents$778 $265 
Accounts receivable and other current assets515 608 
Long-term investments788 39 
Property, equipment and capitalized software1,052 633 
Deferred tax assets1,035 — 
Goodwill and other intangible assets317 445 
Other long-term assets439 246 
Remeasurement of assets of businesses held for sale to fair value less cost to sell(1)
— (1,225)
Total assets$4,924 $1,011 
Liabilities
Medical costs payable$701 $179 
Accounts payable and other current liabilities834 378 
Other long-term liabilities136 524 
Total liabilities$1,671 $1,081 
(1)      Includes the effect of $867 million of cumulative foreign currency translation losses and $52 million of noncontrolling interests.
v3.24.2.u1
Segment Financial Information (Tables)
 6 Months Ended
Jun. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following tables present reportable segment financial information:
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Three Months Ended June 30, 2024
Revenues - unaffiliated customers:
Premiums$70,950 $5,947 $— $— $— $5,947 $— $76,897 
Products— 62 41 12,108 — 12,211 — 12,211 
Services2,388 4,083 1,405 874 — 6,362 — 8,750 
Total revenues - unaffiliated customers
73,338 10,092 1,446 12,982 — 24,520 — 97,858 
Total revenues - affiliated customers
— 16,576 3,070 19,373 (1,129)37,890 (37,890)— 
Investment and other income
528 382 27 60 — 469 — 997 
Total revenues$73,866 $27,050 $4,543 $32,415 $(1,129)$62,879 $(37,890)$98,855 
Earnings from operations$4,004 $1,919 $546 $1,406 $— $3,871 $— $7,875 
Interest expense— — — — — — (985)(985)
Loss on sale of subsidiary and subsidiaries held for sale(1,225)— — — — — — (1,225)
Earnings before income taxes
$2,779 $1,919 $546 $1,406 $— $3,871 $(985)$5,665 
Three Months Ended June 30, 2023
Revenues - unaffiliated customers:
Premiums$67,047 $5,427 $— $— $— $5,427 $— $72,474 
Products— 51 39 10,561 — 10,651 — 10,651 
Services2,584 3,541 1,995 543 — 6,079 — 8,663 
Total revenues - unaffiliated customers
69,631 9,019 2,034 11,104 — 22,157 — 91,788 
Total revenues - affiliated customers
— 14,454 2,615 17,496 (893)33,672 (33,672)— 
Investment and other income
600 444 25 46 — 515 — 1,115 
Total revenues$70,231 $23,917 $4,674 $28,646 $(893)$56,344 $(33,672)$92,903 
Earnings from operations$4,358 $1,525 $968 $1,206 $— $3,699 $— $8,057 
Interest expense— — — — — — (828)(828)
Earnings before income taxes
$4,358 $1,525 $968 $1,206 $— $3,699 $(828)$7,229 
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Six Months Ended June 30, 2024
Revenues - unaffiliated customers:
Premiums$143,243 $11,642 $— $— $— $11,642 $— $154,885 
Products— 121 82 23,917 — 24,120 — 24,120 
Services4,917 8,053 3,107 1,561 — 12,721 — 17,638 
Total revenues - unaffiliated customers
148,160 19,816 3,189 25,478 — 48,483 — 196,643 
Total revenues - affiliated customers
— 33,193 5,801 37,654 (2,145)74,503 (74,503)— 
Investment and other income
1,063 772 55 118 — 945 — 2,008 
Total revenues$149,223 $53,781 $9,045 $63,250 $(2,145)$123,931 $(74,503)$198,651 
Earnings from operations$8,399 $3,818 $1,036 $2,553 $— $7,407 $— $15,806 
Interest expense— — — — — — (1,829)(1,829)
Loss on sale of subsidiary and subsidiaries held for sale(8,311)— — — — — — (8,311)
Earnings before income taxes
$88 $3,818 $1,036 $2,553 $— $7,407 $(1,829)$5,666 
Six Months Ended June 30, 2023
Revenues - unaffiliated customers:
Premiums$134,505 $10,755 $— $— $— $10,755 $— $145,260 
Products— 95 79 20,744 — 20,918 — 20,918 
Services5,139 6,630 3,921 1,053 — 11,604 — 16,743 
Total revenues - unaffiliated customers
139,644 17,480 4,000 21,797 — 43,277 — 182,921 
Total revenues - affiliated customers
— 28,720 5,125 34,175 (1,752)66,268 (66,268)— 
Investment and other income
1,055 721 45 92 — 858 — 1,913 
Total revenues$140,699 $46,921 $9,170 $56,064 $(1,752)$110,403 $(66,268)$184,834 
Earnings from operations$8,701 $3,301 $1,875 $2,266 $— $7,442 $— $16,143 
Interest expense— — — — — — (1,582)(1,582)
Earnings before income taxes
$8,701 $3,301 $1,875 $2,266 $— $7,442 $(1,582)$14,561 
v3.24.2.u1
Basis of Presentation (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2024
Dec. 31, 2023
Nature of Operations
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
  
Accounts Receivable, after Allowance for Credit Loss, Current $ 23,115 $ 21,276
Revenue, Remaining Performance Obligation, Amount $ 14,000  
Revenue, Remaining Performance Obligation, Percentage 50.00%  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 3 years  
unh:ProductsandservicesMember    
Accounts Receivable, after Allowance for Credit Loss, Current $ 9,000 $ 8,600
v3.24.2.u1
Investments (Narrative) (Details)
$ in Millions
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Investments [Abstract]    
Equity Securities, FV-NI and without Readily Determinable Fair Value $ 4,200 $ 4,900
Equity Method Investments $ 1,700 $ 1,400
Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions 33,000  
Total number of security positions 40,000  
v3.24.2.u1
Investments (Short-Term and Long-Term Investments) (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost $ 47,713 $ 47,451
Securities, Available for sale Debt Securities, Gross Unrealized Gains 21 134
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (3,000) (2,690)
Debt Securities, Available-for-sale 44,734 44,895
Held-to-maturity securities, Amortized Cost 565 603
Securities, Held to maturity, Unrecognized Holding Gain 0 1
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss (7) (8)
Debt Securities, Held-to-maturity, Fair Value 558 596
Debt Securities, Available-for-Sale and Held-to-Maturity, Fair Value 45,292 45,491
Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Loss (3,007) (2,698)
Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Gain 21 135
Debt Securities, Available-for-Sale and Held-to-Maturity, Amortized Cost 48,278 48,054
Debt Securities [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale 44,734 44,895
U.S. Government and Agency Obligations [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 5,007 4,674
Securities, Available for sale Debt Securities, Gross Unrealized Gains 0 3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (264) (234)
Debt Securities, Available-for-sale 4,743 4,443
Held-to-maturity securities, Amortized Cost 413 506
Securities, Held to maturity, Unrecognized Holding Gain 0 1
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss (4) (6)
Debt Securities, Held-to-maturity, Fair Value 409 501
State and Municipal Obligations [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 7,299 7,636
Securities, Available for sale Debt Securities, Gross Unrealized Gains 4 39
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (397) (322)
Debt Securities, Available-for-sale 6,906 7,353
Held-to-maturity securities, Amortized Cost 28 28
Securities, Held to maturity, Unrecognized Holding Gain 0 0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss (3) (2)
Debt Securities, Held-to-maturity, Fair Value 25 26
Corporate Obligations [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 23,193 23,136
Securities, Available for sale Debt Securities, Gross Unrealized Gains 14 67
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (1,222) (1,186)
Debt Securities, Available-for-sale 21,985 22,017
Held-to-maturity securities, Amortized Cost 124 69
Securities, Held to maturity, Unrecognized Holding Gain 0 0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss 0 0
Debt Securities, Held-to-maturity, Fair Value 124 69
U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 9,320 8,982
Securities, Available for sale Debt Securities, Gross Unrealized Gains 3 22
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (899) (708)
Debt Securities, Available-for-sale 8,424 8,296
Non-U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 2,894 3,023
Securities, Available for sale Debt Securities, Gross Unrealized Gains 0 3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (218) (240)
Debt Securities, Available-for-sale $ 2,676 $ 2,786
v3.24.2.u1
Investments (Amortized Cost and Fair Value of Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Schedule of Investments [Line Items]    
Due in one year or less, Amortized Cost $ 5,172  
Due after one year through five years, Amortized Cost 14,656  
Due after five years through ten years, Amortized Cost 10,930  
Due after ten years, Amortized Cost 4,741  
Total debt securities - available-for-sale, Amortized Cost 47,713 $ 47,451
Due in one year or less, Fair Value 5,137  
Due after one year through five years, Fair Value 14,021  
Due after five years through ten years, Fair Value 10,044  
Due after ten years, Fair Value 4,432  
Debt Securities, Available-for-sale 44,734 44,895
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One 363  
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five 171  
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 14  
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 17  
Debt Securities, Held-to-maturity 565 603
Held-to-maturity Securities, Debt Maturities, within One Year, Fair Value 362  
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five 168  
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 13  
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 15  
Debt Securities, Held-to-maturity, Fair Value 558 596
U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Mortgage-backed securities, Amortized Cost 9,320  
Total debt securities - available-for-sale, Amortized Cost 9,320 8,982
Mortgage-backed securities, Fair Value 8,424  
Debt Securities, Available-for-sale 8,424 8,296
Non-U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Mortgage-backed securities, Amortized Cost 2,894  
Total debt securities - available-for-sale, Amortized Cost 2,894 3,023
Mortgage-backed securities, Fair Value 2,676  
Debt Securities, Available-for-sale $ 2,676 $ 2,786
v3.24.2.u1
Investments (Fair Value of Available-For-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Debt Securities [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value $ 11,377 $ 5,619
Less Than 12 Months, Gross Unrealized Losses (137) (49)
Greater Than 12 Months, Fair Value 28,841 28,107
Greater Than 12 Months, Gross Unrealized Losses (2,863) (2,641)
Total, Fair Value 40,218 33,726
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (3,000) (2,690)
U.S. Government and Agency Obligations [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 1,187 1,270
Less Than 12 Months, Gross Unrealized Losses (9) (7)
Greater Than 12 Months, Fair Value 2,773 2,077
Greater Than 12 Months, Gross Unrealized Losses (255) (227)
Total, Fair Value 3,960 3,347
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (264) (234)
State and Municipal Obligations [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 1,942 907
Less Than 12 Months, Gross Unrealized Losses (30) (7)
Greater Than 12 Months, Fair Value 4,584 4,063
Greater Than 12 Months, Gross Unrealized Losses (367) (315)
Total, Fair Value 6,526 4,970
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (397) (322)
Corporate Obligations [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 5,334 1,826
Less Than 12 Months, Gross Unrealized Losses (49) (17)
Greater Than 12 Months, Fair Value 13,570 14,696
Greater Than 12 Months, Gross Unrealized Losses (1,173) (1,169)
Total, Fair Value 18,904 16,522
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (1,222) (1,186)
U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 2,511 1,337
Less Than 12 Months, Gross Unrealized Losses (45) (12)
Greater Than 12 Months, Fair Value 5,757 5,069
Greater Than 12 Months, Gross Unrealized Losses (854) (696)
Total, Fair Value 8,268 6,406
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (899) (708)
Non-U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 403 279
Less Than 12 Months, Gross Unrealized Losses (4) (6)
Greater Than 12 Months, Fair Value 2,157 2,202
Greater Than 12 Months, Gross Unrealized Losses (214) (234)
Total, Fair Value 2,560 2,481
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $ (218) $ (240)
v3.24.2.u1
Fair Value (Narrative) (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Fair Value [Line Items]    
Transfers Into Level 3 $ 0 $ 0
Transfers out of Level 3 0 0
Significant fair value adjustments for assets and liabilities measured on a nonrecurring basis $ 0 $ 0
v3.24.2.u1
Fair Value (Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 26,286 $ 25,427
Debt Securities, Available-for-sale 44,734 44,895
Equity Securities, FV-NI 1,786 2,553
Assets under management 3,414 3,755
Assets, Fair Value Disclosure 76,220 76,630
Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 44,734 44,895
U.S. Government and Agency Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 4,743 4,443
State and Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 6,906 7,353
Corporate Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 21,985 22,017
U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 8,424 8,296
Non-U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 2,676 2,786
Quoted Prices in Active Markets (Level 1) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 26,070 25,345
Equity Securities, FV-NI 1,701 2,468
Assets under management 1,414 1,505
Assets, Fair Value Disclosure 33,776 33,500
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 4,591 4,182
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 4,571 4,167
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 20 15
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Other Observable Inputs (Level 2) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 216 82
Equity Securities, FV-NI 16 16
Assets under management 1,893 2,140
Assets, Fair Value Disclosure 42,071 42,749
Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 39,946 40,511
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 172 276
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 6,906 7,353
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 21,768 21,800
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 8,424 8,296
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 2,676 2,786
Unobservable Inputs (Level 3) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 0 0
Equity Securities, FV-NI 69 69
Assets under management 107 110
Assets, Fair Value Disclosure 373 381
Unobservable Inputs (Level 3) [Member] | Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 197 202
Unobservable Inputs (Level 3) [Member] | U.S. Government and Agency Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Unobservable Inputs (Level 3) [Member] | State and Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Unobservable Inputs (Level 3) [Member] | Corporate Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 197 202
Unobservable Inputs (Level 3) [Member] | U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Unobservable Inputs (Level 3) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale $ 0 $ 0
v3.24.2.u1
Fair Value (Financial Assets and Liabilities, Not Measured at Fair Value on a Recurring Basis) (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value $ 558 $ 596
Debt Securities, Held-to-maturity 565 603
Fair Value, Nonrecurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value 558 596
Debt and other financing obligations 61,144 59,851
Fair Value, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value 531 524
Debt and other financing obligations 0 0
Fair Value, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value 27 72
Debt and other financing obligations 61,144 59,851
Fair Value, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value 0 0
Debt and other financing obligations 0 0
Long-term debt and other financing obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt and other financing obligations, carrying value $ 65,186 $ 61,449
v3.24.2.u1
Medical Costs Payable (Narrative) (Details) - USD ($)
$ in Billions
Jun. 30, 2024
Dec. 31, 2023
Insurance [Abstract]    
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount $ 23.6 $ 22.3
v3.24.2.u1
Medical Costs Payable (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]    
Medical costs payable, beginning of period $ 32,395 $ 29,056
Acquisitions (dispositions), net (687) 1
Reported medical costs:    
Current year 131,583 120,773
Prior year (390) (660)
Total reported medical costs 131,193 120,113
Medical payments:    
Payments for current year (102,288) (91,621)
Payments for prior years (27,887) (25,602)
Total medical payments (130,175) (117,223)
Less: medical costs payable included within businesses held for sale (179) 0
Medical costs payable, end of period $ 32,547 $ 31,947
v3.24.2.u1
Short-Term Borrowings and Long-Term Debt (Details) - USD ($)
$ in Millions
Jul. 31, 2024
Mar. 31, 2024
Debt Instrument [Line Items]    
Par Value   $ 6,000
Subsequent Event    
Debt Instrument [Line Items]    
Par Value $ 12,000  
4.600% notes due April 2027    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   4.60%
Par Value   $ 500
4.700% notes due April 2029    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   4.70%
Par Value   $ 400
4.900% notes due April 2031    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   4.90%
Par Value   $ 1,000
5.000% notes due April 2034    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   5.00%
Par Value   $ 1,250
5.375% Notes due April 2054    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   5.375%
Par Value   $ 1,750
5.500% Notes due April 2064    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   5.50%
Par Value   $ 1,100
Floating rate notes due July 2026 | Subsequent Event    
Debt Instrument [Line Items]    
Par Value $ 500  
4.750% notes due July 2026 | Subsequent Event    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 4.75%  
Par Value $ 650  
4.800% notes due January 2030 | Subsequent Event    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 4.80%  
Par Value $ 1,250  
4.950% notes due January 2032 | Subsequent Event    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 4.95%  
Par Value $ 1,500  
5.150% notes due July 2034 | Subsequent Event    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 5.15%  
Par Value $ 2,000  
5.500% notes due July 2044 | Subsequent Event    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 5.50%  
Par Value $ 1,500  
5.625% notes due July 2054 | Subsequent Event    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 5.625%  
Par Value $ 2,750  
5.750% notes due July 2064 | Subsequent Event    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 5.75%  
Par Value $ 1,850  
v3.24.2.u1
Short-Term Borrowings and Long-Term Debt (Narrative) (Details) - USD ($)
$ in Millions
 6 Months Ended
Jun. 30, 2024
Jul. 31, 2024
May 31, 2024
Mar. 31, 2024
Debt Instrument [Line Items]        
Par Value       $ 6,000
Subsequent Event        
Debt Instrument [Line Items]        
Par Value   $ 12,000    
May 2024 364-day revolving bank credit facility [Member]        
Debt Instrument [Line Items]        
Line of Credit Facility, Expiration Period 364 days      
Par Value     $ 3,000  
May 2024 364-day delayed draw term loan        
Debt Instrument [Line Items]        
Line of Credit Facility, Expiration Period 364 days      
Par Value     $ 5,000  
Commercial Paper [Member]        
Debt Instrument [Line Items]        
Commercial Paper $ 9,900      
Short-term Debt, Weighted Average Interest Rate, at Point in Time 5.40%      
v3.24.2.u1
Shareholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 25, 2024
Mar. 19, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Equity [Abstract]            
Common Stock, Dividends, Per Share, Cash Paid $ 2.10 $ 1.88 $ 2.10 $ 1.88 $ 3.98 $ 3.53
Payments of Ordinary Dividends, Common Stock $ 1,935 $ 1,729     $ 3,664 $ 3,284
v3.24.2.u1
Shareholders' Equity (Narrative) (Details)
shares in Millions
Jun. 30, 2024
shares
Equity [Abstract]  
Share Repurchase Program, Authorized, Number of Shares 35
Share Repurchase Program, Remaining Authorized, Number of Shares 44
v3.24.2.u1
Commitments and Contingencies (Narrative) (Details) - USD ($)
$ in Billions
 1 Months Ended 6 Months Ended
Jul. 31, 2024
Jun. 30, 2024
Contingencies [Line Items]    
Other Commitment   $ 6
Other Commitments, Description   As of June 30, 2024, the Company had entered into transaction agreements in the health care sector, subject to regulatory approval and/or other customary closing conditions. The total anticipated consideration required for these transactions, excluding the payoff of acquired indebtedness, was approximately $6 billion
Subsequent Event    
Contingencies [Line Items]    
Subsequent Event, Description In July, 2024, the Company completed transactions in the health care sector for total consideration of approximately $10 billion.  
Other Commitment $ 10  
v3.24.2.u1
Disposition and Held for Sale (Narrative) (Details)
$ in Millions
 6 Months Ended
Jun. 30, 2024
USD ($)
Brazil Disposal Group  
Disposition and Held for Sale [Line Items]  
Loss on sale of subsidiary $ (7,100)
Foreign Currency Translation Loss (4,100)
Businesses Held for Sale  
Disposition and Held for Sale [Line Items]  
Loss on sale of subsidiary (1,200)
Foreign Currency Translation Loss $ (867)
v3.24.2.u1
Disposition and Held for Sale (Details) - USD ($)
$ in Millions
Jun. 30, 2024
Feb. 06, 2024
Brazil Disposal Group    
Disposition and Held for Sale [Line Items]    
Cash and cash equivalents   $ 778
Accounts receivable and other current assets   515
Long-term investments   788
Property, equipment and capitalized software   1,052
Deferred tax assets   1,035
Goodwill and other intangible assets   317
Other long-term assets   439
Remeasurement of assets of businesses held for sale to fair value less cost to sell   0
Total assets   4,924
Medical costs payable   701
Accounts payable and other current liabilities   834
Other long-term liabilities   136
Total liabilities   $ 1,671
Businesses Held for Sale    
Disposition and Held for Sale [Line Items]    
Cash and cash equivalents $ 265  
Accounts receivable and other current assets 608  
Long-term investments 39  
Property, equipment and capitalized software 633  
Deferred tax assets 0  
Goodwill and other intangible assets 445  
Other long-term assets 246  
Remeasurement of assets of businesses held for sale to fair value less cost to sell (1,225)  
Total assets 1,011  
Medical costs payable 179  
Accounts payable and other current liabilities 378  
Other long-term liabilities 524  
Total liabilities 1,081  
Noncontrolling interests included in determination of remeasurement losses 52  
Foreign currency losses included in calculation of remeasurement loss on disposal groups held for sale $ 867  
v3.24.2.u1
Segment Financial Information (Narrative) (Details)
 6 Months Ended
Jun. 30, 2024
reportableSegments
Statement [Line Items]  
Number of Reportable Segments 4
v3.24.2.u1
Segment Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Statement [Line Items]        
Premiums, revenues - unaffiliated customers $ 76,897 $ 72,474 $ 154,885 $ 145,260
Investment and other income 997 1,115 2,008 1,913
Total revenues 98,855 92,903 198,651 184,834
Earnings from operations 7,875 8,057 15,806 16,143
Interest expense (985) (828) (1,829) (1,582)
Loss on sale of subsidiary and subsidiaries held for sale (1,225) 0 (8,311) 0
Earnings before income taxes 5,665 7,229 5,666 14,561
Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 12,211 10,651 24,120 20,918
Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 8,750 8,663 17,638 16,743
Optum        
Statement [Line Items]        
Investment and other income 469 515 945 858
Total revenues 62,879 56,344 123,931 110,403
Earnings from operations 3,871 3,699 7,407 7,442
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 3,871 3,699 7,407 7,442
Unaffiliated Customers        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 76,897 72,474 154,885 145,260
Total revenues 97,858 91,788 196,643 182,921
Unaffiliated Customers | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 12,211 10,651 24,120 20,918
Unaffiliated Customers | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 8,750 8,663 17,638 16,743
Unaffiliated Customers | Optum        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 5,947 5,427 11,642 10,755
Total revenues 24,520 22,157 48,483 43,277
Unaffiliated Customers | Optum | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 12,211 10,651 24,120 20,918
Unaffiliated Customers | Optum | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 6,362 6,079 12,721 11,604
Affiliated Customers        
Statement [Line Items]        
Total revenues 0 0 0 0
Affiliated Customers | Optum        
Statement [Line Items]        
Total revenues 37,890 33,672 74,503 66,268
Operating Segments | UnitedHealthcare        
Statement [Line Items]        
Investment and other income 528 600 1,063 1,055
Total revenues 73,866 70,231 149,223 140,699
Earnings from operations 4,004 4,358 8,399 8,701
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale (1,225)   (8,311)  
Earnings before income taxes 2,779 4,358 88 8,701
Operating Segments | Optum Health        
Statement [Line Items]        
Investment and other income 382 444 772 721
Total revenues 27,050 23,917 53,781 46,921
Earnings from operations 1,919 1,525 3,818 3,301
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 1,919 1,525 3,818 3,301
Operating Segments | Optum Insight        
Statement [Line Items]        
Investment and other income 27 25 55 45
Total revenues 4,543 4,674 9,045 9,170
Earnings from operations 546 968 1,036 1,875
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 546 968 1,036 1,875
Operating Segments | Optum Rx        
Statement [Line Items]        
Investment and other income 60 46 118 92
Total revenues 32,415 28,646 63,250 56,064
Earnings from operations 1,406 1,206 2,553 2,266
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 1,406 1,206 2,553 2,266
Operating Segments | Unaffiliated Customers | UnitedHealthcare        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 70,950 67,047 143,243 134,505
Total revenues 73,338 69,631 148,160 139,644
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 2,388 2,584 4,917 5,139
Operating Segments | Unaffiliated Customers | Optum Health        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 5,947 5,427 11,642 10,755
Total revenues 10,092 9,019 19,816 17,480
Operating Segments | Unaffiliated Customers | Optum Health | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 62 51 121 95
Operating Segments | Unaffiliated Customers | Optum Health | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 4,083 3,541 8,053 6,630
Operating Segments | Unaffiliated Customers | Optum Insight        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 0 0 0 0
Total revenues 1,446 2,034 3,189 4,000
Operating Segments | Unaffiliated Customers | Optum Insight | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 41 39 82 79
Operating Segments | Unaffiliated Customers | Optum Insight | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 1,405 1,995 3,107 3,921
Operating Segments | Unaffiliated Customers | Optum Rx        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 0 0 0 0
Total revenues 12,982 11,104 25,478 21,797
Operating Segments | Unaffiliated Customers | Optum Rx | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 12,108 10,561 23,917 20,744
Operating Segments | Unaffiliated Customers | Optum Rx | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 874 543 1,561 1,053
Operating Segments | Affiliated Customers | UnitedHealthcare        
Statement [Line Items]        
Total revenues 0 0 0 0
Operating Segments | Affiliated Customers | Optum Health        
Statement [Line Items]        
Total revenues 16,576 14,454 33,193 28,720
Operating Segments | Affiliated Customers | Optum Insight        
Statement [Line Items]        
Total revenues 3,070 2,615 5,801 5,125
Operating Segments | Affiliated Customers | Optum Rx        
Statement [Line Items]        
Total revenues 19,373 17,496 37,654 34,175
Optum Eliminations        
Statement [Line Items]        
Investment and other income 0 0 0 0
Total revenues (1,129) (893) (2,145) (1,752)
Earnings from operations 0 0 0 0
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 0 0 0 0
Optum Eliminations | Unaffiliated Customers        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 0 0 0 0
Total revenues 0 0 0 0
Optum Eliminations | Unaffiliated Customers | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Optum Eliminations | Unaffiliated Customers | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Optum Eliminations | Affiliated Customers        
Statement [Line Items]        
Total revenues (1,129) (893) (2,145) (1,752)
Corporate and Eliminations        
Statement [Line Items]        
Investment and other income 0 0 0 0
Total revenues (37,890) (33,672) (74,503) (66,268)
Earnings from operations 0 0 0 0
Interest expense (985) (828) (1,829) (1,582)
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes (985) (828) (1,829) (1,582)
Corporate and Eliminations | Unaffiliated Customers        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 0 0 0 0
Total revenues 0 0 0 0
Corporate and Eliminations | Unaffiliated Customers | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Corporate and Eliminations | Unaffiliated Customers | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Corporate and Eliminations | Affiliated Customers        
Statement [Line Items]        
Total revenues $ (37,890) $ (33,672) $ (74,503) $ (66,268)
UnitedHealth (NYSE:UNH)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more UnitedHealth Charts.
UnitedHealth (NYSE:UNH)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more UnitedHealth Charts.